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“…the process of experimental science does not consist in explaining the unknown by
the known, as in certain mathematical proofs. It aims, on the contrary, to give an
account of what is observed by the properties of what is imagined. To explain the
visible by the invisible. And it is through the evolution of the invisible, through an
appeal to new hidden structures, with hypothetical properties, that science proceeds.”
-François Jacob
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ABSTRACT
Germline mutations in fumarate hydratase (FH) cause hereditary leiomyomatosis and
renal cell  cancer (HLRCC). FH is a nuclear encoded enzyme which functions in the
Krebs tricarboxylic acid cycle, and homozygous mutation in FH lead to severe
developmental defects. Both uterine and cutaneous leiomyomas are components of
the HLRCC phenotype. Most of these tumours show loss of the wild-type allele and,
also, the mutations reduce FH enzyme activity, which indicate that FH is a tumour
suppressor gene. The renal cell cancers associated with HLRCC are of rare papillary
type 2 histology. Other genes involved in the Krebs cycle, which are also implicated
in neoplasia are 3 of the 4 subunits encoding succinate dehydrogenase (SDH);
mutations in SHDB, SDHC, and SDHD predispose to paraganglioma and
phaeochromocytoma.
Although uterine leiomyomas (or fibroids) are very common, the estimations
of affected women ranging from 25% to 77%, not much is known about their genetic
background. Cytogenetic studies have revealed that rearrangements involving
chromosomes 6, 7, 12 and 14 are most commonly seen in fibroids. Deletions on the
long arm of chromosome 7 have been reported to be involved in about 17 to 34 % of
leiomyomas and the small commonly deleted region on 7q22 suggests that there
might be an underlying tumour suppressor gene in that region.
The purpose of this study was to investigate the genetic mechanisms behind
the development of tumours associated with HLRCC, both renal cell cancer and
uterine fibroids. Firstly, a database search at the Finnish cancer registry was
conducted  in  order  to  identify  new families  with  early-onset  RCC and to  test  if  the
family history was compatible with HLRCC. Secondly, sporadic uterine fibroids were
tested for deletions on 7q in order to define the minimal deleted 7q-region, followed
by mutation analysis of the candidate genes. Thirdly, oligonucleotide chips were
utilised to study the global gene expression profiles of uterine fibroids in order to test
whether 7q-deletions and FH mutations significantly affected fibroid biology.
In the screen for early-onset RCC, 214 families were identified. Subsequently,
the pedigrees were constructed and clinical data obtained. One of the index cases
(RCC at the age of 28) had a mother who had been diagnosed with a heart tumour,
which in further investigation turned out to be a paraganglioma. This lead to an
12
alternative hypothesis that SDH, instead of FH, could be involved. SDHA, SDHB,
SDHC and SDHD were sequenced from these individuals; a germline SDHB R27X
mutation was detected with loss of the wild-type allele in both tumours. These results
suggest that germline mutations in the SDHB gene  predispose  to  early-onset  RCC
establishing a novel form of hereditary RCC. This has immediate clinical implications
in the surveillance of patients suffering from early-onset RCC and
phaeochromocytoma/paraganglioma.
For the studies on sporadic uterine fibroids, a set of 166 fibroids from 51
individuals were collected. The 7q LOH mapping defined a commonly deleted region
of about 3.2 mega bases (Mb) in 11 of the 166 tumours. The deletion was consistent
with previously reported allelotyping studies of leiomyomas and it therefore
suggested the presence of a tumour suppressor gene in the deleted region.
Furthermore, the high-resolution aCGH-chip analysis refined the deleted region to
only 2.79 Mb. When combined with previous data, the commonly deleted region was
only 2.3 Mb. The mutation screening of the known genes within the commonly
deleted region did not reveal pathogenic mutations, however.
The expression microarray analysis revealed that FH-deficient fibroids, both
sporadic and familial, had their distinct gene expression profile as they formed their
own group in the unsupervised clustering. On the other hand, the presence or absence
of 7q-deletions did not significantly alter the global gene expression pattern of
fibroids,  suggesting  that  these  two  groups  do  not  have  different  biological
backgrounds. Multiple differentially expressed genes were identified between FH
wild-type and FH-mutant fibroids, and the most significant increase was seen in the



















The background of this particular work was laid when a person from a family with
apparent familial clustering of renal cell cancer (RCC) was referred to genetic
counselling some time during the mid-1990s. Instead of just adding the files to the
pile of previously uncharacterised, but still probable cases of inherited renal cancer,
the clinician, Dr. Outi Vierimaa, dug into the family’s medical history thoroughly.
This lead to the recognition of other clinical features that seemed to belong to the
phenotype, namely cutaneous and uterine leiomyomas. The next step was to contact
Professor Lauri A. Aaltonen, who had a lot of experience in mapping the genes
responsible for hereditary cancer. The clinical observation had led to a scientific
hypothesis that was to be rigorously tested in subsequent experimental work in the
laboratory. With enormous amounts of time and effort, the gene responsible for the
new syndrome was first mapped to a particular region of the genome, and
subsequently cloned. The molecular background of a new tumour predisposition
syndrome, hereditary leiomyomatosis and renal cell cancer (HLRCC), had been
elucidated.
This process that lead from the original clinical observation into the scientific
success story is depicted in Figure 1. This scheme of thought is not complete, nor
does it take into account much of the literature of the philosophy of science, but it still
has been important during this
work. It owes a great deal to
the ideas of Karl R. Popper
and his theory of scientific
discovery. Whether the
important thing in the process
is the question, as François
Jacob has put it, or the
hypothesis, in the spirit of
Popper, most theoretical views
on practical everyday science are oversimplified. Still, it is important that everyone
involved in the process of scientific research understands, at least in some personal
Figure 1.
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way, logic behind their work. If not, the justification of the whole scientific research
is wiped away: There is no science.
The work described here belongs to the second generation of experiments
following  the  first  scientific  success  after  the  initial  clinical  observation.  If  the  gene
would not have been identified, which indeed is the case rather often, the whole
process would have stopped. On the contrary, the identification of the gene has lead to
a huge number of different lines of research that all  are linked through the common
origin, the FH gene. This work is one small part of the research that has followed the
discovery of the molecular background of HLRCC.
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2 REVIEW OF THE LITERATURE
2.1  Some landmarks in tumour genetics
Although some opportunistic views still persist, cancer is generally thought as being a
disease of genes (Vogelstein and Kinzler 2002). The first recognition of chromosome
abnormalities as a cause of abnormal growth came through the studies of Theodor
Boveri (1862-1915). He used sea urchin eggs to analyse the consequences of
chromosome rearrangement on cell division, which lead him to postulate that similar
aberrations could be the underlying cause of human malignancies (Balmain 2001,
Wunderlich 2002). After this initial discovery, Boveri went on to make several
predictions on the nature of human cancer that were to be supported by experimental
results only decades later. For example, he foresaw the existence of cell-cycle
checkpoints, tumour suppressor genes, oncogenes, the progression of tumours from
benign lesions into malignant cancer, the clonality of tumours, cancer predisposition
through inheritance of chromosomes, and the inheritance of some weak chromosomes
that would, when homozygous, lead to high-penetrance cancer predisposition. These
theoretical ideas were presented in his publication “Zur Frage der Entstehung
Maligner Tumoren” in 1914.
The development of molecular biology through studies that showed that the
substance transmitting inheritance was deoxyribonucleic acid (DNA) (Avery et al.
1944), the subsequent discovery of DNA structure (Watson and Crick 1953a, and
1953b), and the unravelling of the genetic code (Crick et al. 1961) lay further
emphasis on the importance of the genetic component on the development of human
disease. This was also reflected in the field of cancer research and lead to several
landmark discoveries which still make the foundation of our current understanding of
cancer.
Firstly, the development of cytogenetic techniques enabled the detection of
chromosomal abnormalities in specific types of cancer, the first example of which is
the Philadelphia chromosome described in chronic myeloid leukaemia in 1960
(Nowell and Hungerford). The specific chromosomal aberration underlying the
Philadelphia chromosome was identified a decade later (Rowley 1973), after which
the characterisation of the gene product resulting from the chromosomal abnormality
became possible (Heisterkamp et al. 1983, de Klein et al. 1982). Later, several other
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recurrent chromosomal aberrations have been detected in various cancers, and large
scale somatic alterations are thought to be an important characteristic of several
human tumours (Lengauer et al. 1998).
The  second  landmark  in  the  history  of  cancer  genetics  was  the  discovery  of
oncogenes. The preliminary findings that cell-free mediators could transfer tumours
from one chicken to another were made by Rous (1910, and 1911). His work was
followed by a number of studies on the Rous Sarcoma Virus (RSV), and similar
viruses were thought to be responsible for most, if not all cancers (Huebner and
Todaro 1969). However, the discovery that the transforming agent in these viruses
was an RNA sequence (Duesberg and Vogt 1970), and that this sequence had
homologues in normal avian DNA (Stehelin et al. 1976) suggested that the viruses
had obtained their transforming capability by “kidnapping” normal avian genes. Thus,
it was proposed that tumours could arise without the involvement of viruses. First
results supporting this hypothesis came when it was shown that DNA from chemically
mutagenised transformed mouse cells could transform normal cells (Shih et al. 1979).
Transforming sequences were subsequently extracted from human cancer as well, and
soon the gene responsible for the process was identified as a cellular homologue of
the Harvey and Kirsten sarcoma virus gene, ras (Parada et al. 1982). Initially the
difference between the normal c-Ha-RAS1 and the transforming counterpart from the
carcinoma  was  not  clear.  Soon,  however,  the  responsible  amino  acid  change  in  the
carcinoma cell line was identified at codon 12 (Reddy et al. 1982, Tabin et al. 1982),
and subsequent research has shown that this mutation alters the protein as being
constitutively active. Thus, molecular evidence for the presence of dominantly acting
oncogenes had been produced and, subsequently, several dominantly acting cancer
genes have been identified, some of which can also cause hereditary cancer (Futreal et
al. 2004).
The final landmark has been the discovery of tumour suppressor genes. The
familial clustering of cancer had been obvious from clinical observations for a long
time, but the first theory that allowed the molecular testing of specific hypothesis on
familial cancer came from the studies by Knudson (1971) on familial and sporadic
retinoblastoma. He proposed a model according to which cancer arose through two
hits on a cancer gene. This theory predicted that a gene acting recessively at the
cellular level, a tumour suppressor gene, needed either a germline mutation and a
somatic mutation, or alternatively, two somatic mutations for tumour development.
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After the appropriate methodology became available for molecular detection of
particular parental alleles, Knudson’s theory led to the chromosomal mapping
(Cavenee et al. 1983) and cloning (Friend et al. 1986) of the first tumour suppressor
gene, RB. Since then, several recessively acting cancer genes have been discovered
and, currently, more recessive than dominant cancer genes are known (Futreal et al.
2004).
2.2  Defining cancer
2.2.1 The number of mutations in tumours
Although it is not entirely clear whether all cancers are actually genetic diseases, as
some might, at least theoretically, develop solely due to epigenetic changes, the study
of mutations in cancer has proven an excellent approach to unravel the biology of
many tumours. Early studies that applied mathematical models on mortality rates and
epidemiological data concluded that cancer could not result from a single genetic hit.
The first estimations were that around 7 mutations were required (Armitage and Doll
1954, Nordling 1953), and further refinement of the models suggested that 2
mutations could be enough (Armitage and Doll 1957). The results by Knudson on
familial and sporadic retinoblastoma further supported the multi-step cancer
progression theory and provided a model that could be further experimentally tested
on the molecular level (Knudson 1971). Some have argued that in order to develop a
sufficient amount of mutations, a cancer has to develop a “mutator phenotype” (Loeb
et al. 1974). This view has, however, been contradicted by others, who have shown
that evolution at the somatic level and the Darwinian selection is more important,
although some cancers may have increased mutation rates that could speed up the
evolutionary process (Tomlinson and Bodmer 1999, Tomlinson et al. 1996).
At present, there are about 350 known genes that are mutated in cancer
(Futreal et al. 2004) (http://www.sanger.ac.uk/genetics/CGP/Census/); they represent
more than 1% of all human genes. Approximately 90% of the cancer genes show
somatic mutations and, in about 20%, germline mutations have been observed. Of the
known somatic mutations, 90% act dominantly at the cellular level, whereas of the
germline mutations, 90% are recessive. An important source for mutational
information in cancers has been derived from recent large-scale resequencing efforts,
which have typically targeted a large group of genes in a particular type or types of
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tumours (Bardelli et al. 2003, Davies et al. 2005, Hunter et al. 2006, Samuels et al.
2004, Stephens et al. 2005, Wang et al. 2004).
The mutations detected in tumours can be divided into different classes, those
that  are  contributing  to  the  tumour  growth  (drivers),  and  those  that  only  reflect  the
mutational processes that have been active during the tumorigenesis, but that do not
contribute to the tumorigenic process (passengers) (Stratton 2006). The number of
driver mutations in a particular tumour is determined by the number of events
required for tumorigenesis, and the pattern of these mutations reflects the mutational
processes and selection. The number of passenger mutations, on the other hand, is
determined by the number of mitoses during development, starting from the first
mitosis in the embryogensis, and the pattern of these mutations solely reflects the
mutational processes. As most mutations detected in an individual tumour are likely
to be passengers, the problem is how to identify the drivers. The comparison of the
amount of silent versus missense and nonsense mutations suggests, however, that
drivers do exist.
A significant contribution to resequencing projects has come from the Sanger
Cancer Genome Project that has focused on protein kinases. Their results indicate that
there might be several different kinases contributing to tumorigenesis, making the
identification of drivers difficult (Davies et al. 2005). Also, based on sequence data
from the kinome, the amount of somatic mutations in an individual tumour has been
estimated to range from less than 2000 to more than 100 000, resulting in 20 to 1000
amino acid changes (Stephens et al. 2005). In addition to leading to the identification
of new genes mutated in different tumour types, these resequencing studies have
provided significant insight into the biology of some of these tumours. For example, a
screen for somatic mutations in breast cancers revealed a possible new mutator
phenotype (Stephens et al. 2005), and a similar study on glioblastomas led to the
identification of a new mechanism enabling tumours to survive and recur after
chemotherapy (Hunter et al. 2006). Similar projects focusing solely on the cancer
genome are likely to provide invaluable information of the biology of various human
tumours in the near future.
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2.2.2 Adenoma-carcinoma sequence
Although evidence supporting the idea of the clonal origin of cancer had emerged
since the recognition of cancer being a genetic disease, it was not until 1976 that
Nowell incorporated this with the idea of multistep tumour development (Nowell
1976). Direct experimental evidence in support of the clonal origin of tumours came
from  studies  on  the  chromosome  X  inactivation  pattern  in  colorectal  cancer  (CRC)
(Fearon et al. 1987), and subsequently similar findings have been seen in other
tumour types (Sidransky et al. 1992). Building on this, Fearon and Vogelstein
constructed their famous genetic model for colorectal tumorigenesis (Fearon and
Vogelstein 1990). They postulated, based on experimental evidence from studies on
colorectal lesions of various stages, that the clonal evolution of tumours is indeed a
multistep process in which the number of genetic hits, rather than the order in which
they accumulate, is the key denominator of each neoplastic lesion. According to this
model, changes in probably at least 5 different genes, the majority of which are
tumour suppressors, were required for the malignant tumour to develop; fewer
changes would be enough for adenomas. Based on evidence from studies on p53,  a
well established tumour suppressor gene, Fearon and Vogelstein argued that some
tumour suppressors are not necessarily recessive on the cellular level, that is, already
the loss of one allele would increase the susceptibility to tumorigenesis. It has also
become evident that the different hits target more precisely different pathways, rather
than different genes (Vogelstein and Kinzler 2004). This notion is based on genetic
evidence from mutation screenings of CRCs, as it has been shown that mutations in
certain genes, such as in APC and -catenin, are mutually exclusive in individual
tumours (Sparks et al. 1998). This is explained by the fact that both mutations are
thought to have the same effect on the APC/ -catenin/Tcf pathway and, therefore,
acquiring mutations in both genes would not confer any further growth advantage.
Although this adenoma-carcinoma sequence is rather well established in CRC, there is
evidence that at least in tumours showing microsatellite instability, carcinomas would
not  develop  from  macroscopic  adenomas  (Tsao  et  al.  2000).  It  does  not  mean,
however, that adenomas and carcinomas could not have a common progenitor, but it
suggests that a slow process through which large adenomas gradually become more
and more malignant is unlikely.
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2.2.3 Gatekeepers, caretakers, and landscapers
Vogelstein has further developed his model on tumorigenesis by dividing the roles of
individual genes into gatekeepers, caretakers, and landscapers (Kinzler and
Vogelstein 1996, and 1998). Gatekeepers are genes that are directly involved in the
regulation of cell birth or cell death. Mutations in these genes, such as VHL, p53, RB,
and APC, are therefore essential for the tumorigenic process and, thus, normally
function as “gatekeepers” to prevent uncontrolled growth. When the function of these
genes is restored in cancer cells, tumour progression and growth is inhibited. Each
cell-type has its own gatekeepers, and the tumour spectrum of different cancer
predisposition syndromes varies. Also, same gatekeepers can act at different stages of
tumour progression in different tissue-types. An example of this are mutations in p53,
as they are present in about 80% of CRCs, but germline mutations in the same gene
do not increase the risk of CRC (Kinzler and Vogelstein 1996).
Caretakers are genes that are involved in the maintenance of cell integrity, for
example through DNA repair (Kinzler and Vogelstein 1997, and 1998). When these
genes are inactivated, cellular processes become unstable therefore leading to
increased rates of mistakes, such as mutations during DNA replication; the DNA
repair genes, such as XPB, ATM, MSH2, and MLH1, are the prototypes of caretakers.
Instead of being directly involved in tumorigenesis, loss-of-function mutations in
these genes facilitate the acquisition of multiple genetic hits, some of which might
promote tumorigenesis. In the case of mismatch repair genes, this is seen as increased
mutation rates of short tandem nucleotide repeats, a phenomenon referred to as
microsatellite instability (Kinzler and Vogelstein 1996). However, as caretakers are
not directly involved in cell proliferation, the restoration of these genes in tumour
cells does not have an effect on tumour growth; only the subsequent tumour evolution
might slow down.
Landscapers, on the other hand, are genes that govern the cellular landscape
(Kinzler and Vogelstein 1998). These genes function at the tissue level and regulate
cells other than those in which they are expressed. An example of these genes is
SMAD4, inherited mutations of which predispose to multiple hamartomatous
gastrointestinal polyps. The increased risk of cancer associated with SMAD4
mutations is thought to arise through abnormal stromal cell compartment, which leads
to defective intercellular signalling with the epithelium, thus facilitating epithelial
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transformation (Kinzler and Vogelstein 1998). More direct evidence on the landscaper
effect has emerged from studies on mouse models. For example, the inactivation of
the transforming growth factor  receptor II in mouse fibroblasts (TGFBR2) has
resulted in intraepithelial neoplasia of the prostate and invasive squamous cell
carcinoma of the forestomach (Bhowmick et al. 2004).
2.2.4 Order of mutations
The idea that only the number of mutations is important, not the order or time-frame
in which they are acquired, has been challenged. At least theoretically, it seems
reasonable that some mutations that are important for a tumour would be deleterious
if acquired at the wrong time. This is due to a strong intrinsic tendency for tumour
suppression that is inherent in all metazoan cells (Lowe et al. 2004), and reflected, for
example, in the fact that oncogenes can cause apoptosis (Evan et al. 1992), and that by
inactivating the apoptotic machinery at the same time, tumorigenesis may proceed
(Pelengaris et al. 2002). In such situations, rescuing normal apoptotic function by
restoring  the  normal  expression  of  a  gene,  for  example  the  tumour  suppressor p53,
could be fatal to the tumour but leave normal cells intact (Lowe et al. 2004). A similar
idea of manipulating cellular pathways in a way which is deleterious for cancer cells
but would have no effect on normal cells comes from the concept of synthetic
lethality (Kaelin 2005). Two genes are synthetically lethal if inactivation of either of
them alone does not have an effect on the cell, but inactivating both of them would
result in severe loss of fitness. Therefore, if a cancer cell harbours mutations in one of
these genes, inactivation of the other would result in selective killing of the tumour
cells. Recent advances in techniques may facilitate the identification of such gene-
pairs in the near future (Kaelin 2006).
2.2.5 The hallmarks of cancer
Hanahan and Weinberg (2000) proposed six underlying principles that would define
the  nature  and  features  of  all  cancers,  namely  self-sufficiency  in  growth  signals,
insensitivity to antigrowth signals, capability to evade apoptosis, limitless replicative
potential, sustained angiogenesis, and capability to invade and metastasise, not
necessary in this order. In contrast to the reductionistic approach only focusing on the
cancer cells themselves, they emphasised the holistic view of cancer, according to
which tumours are complex tissues comprising a number of different cell types, both
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neoplastic and normal. Also, their model of tumorigenesis does not speculate on the
number of independent (genetic) hits required as in some cases one hit can facilitate
the acquisition of more than one of the six hallmarks or, on the other hand, in some
cases multiple hits are required for the development of one hallmark.
2.2.6 Cancer stem cells
An important point, not discussed by the abovementioned models on cancer is the cell
type  from  which  the  tumorigenic  growth  starts  from.  The  idea  that  all  cells  are  not
prone  to  becoming  tumours  is  not  new,  pointing  to  the  direction  of  stem  cells  and,
possibly, to cancer stem cells. Results from mostly haematological cancers suggest
that only a small fraction of tumour cells are actually those maintaining the whole
tumour cell population (Polyak and Hahn 2006). Several models on how a cancer
stem cell developes have been proposed. A normal stem cell can acquire mutations,
leading to the loss of asymmetric cell division and thus leading to increased amounts
of stem cell-like progenitors, which then can acquire more mutations and become
cancer stem cells. Alternatively, several mutations can occur in one stem cell, leading
directly  to  the  formation  of  a  cancer  stem  cell  that  would  supply  the  tumour  with
required non-stem cell-like cells. Still another possibility is that a fully or partially
differentiated cell acquires mutations that make it transform into a stem cell-like state,
for example through epidermal-mesenchymal transition. There is experimental
evidence supporting all these pathways, and it may be, that in different tumour types,
different pathways operate (Polyak and Hahn 2006). In accordance with the cancer
stem cell model, a recent theory suggesting the epigenetic progenitor origin of human
cancer has been proposed (Feinberg et al. 2006). There the authors suggest that the
first step initiating the tumorigenic process is due to abnormalities in tumour-
progenitor genes, which would result in vast epigenetic changes in a stem cell. These
changes would then become present in a larger number of cells in the stem cell
compartment. The second step, which is conceptually the same as the tumour
initiation  step  in  the  Vogelstein  model,  would  be  a  genetic  alteration  facilitating  the
tumour progression and subsequent invasion and metastasis. All tumour stem cell-
based tumour models are supported by the notion that many of the hallmarks of
cancer proposed by Hanahan and Weinberg (2000) are actually properties of normal
stem cells. Therefore, no new genetic hits would be required for them to develop.
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2.3  Tumour suppression: VHL as an example
As was the case with p53, it is not always clear whether a particular gene in which
mutations occur in cancers acts as an oncogene or a tumour suppressor (Sherr 2004).
However, as most of this work is motivated by the tumour suppressor genes, it is
worth  describing  one  of  them  in  more  detail.  As  in  many  cases,  the VHL tumour
suppressor gene was identified through the study of familial cancer. The first report
describing the observation of bilateral vascular growths of the retinas in two siblings
was published in 1894. Similar observations were soon made elsewhere and the
hemangioblastomas of the central nervous system was also linked to the same
syndrome. The term “von Hippel-Lindau (VHL) disease” was first used in 1936 and,
since then, several different tumour types, such as clear-cell renal carcinomas,
phaeochromocytomas, endolymphatic sac tumours of the inner ear, epididymal and
broad ligament cystadenomas, and islet-cell tumours of the pancreas, have been
linked to the syndrome. The prevalence of the VHL syndrome is about 1/35 000, and
it is transmitted in an autosomal dominant manner (Kim and Kaelin 2004).
Genetic linkage analysis mapped the VHL gene to chromosome 3p25, a region
that was known to be frequently deleted in sporadic renal cell cancers (Seizinger et al.
1988). This immediately suggested that the same gene might be involved both in
sporadic and familial RCC. Five years later the gene was identified (Latif et al. 1993)
and, at the same time, mutations were also detected in sporadic RCC. The gene was
found to be evolutionarily conserved, but the predicted gene product did not show
homology to any known proteins. Subsequent studies showed that VHL encoded  a
30kD cytoplasmic protein, pVHL, and when reintroduced to a VHL-mutant RCC cell-
line 786-O, it inhibited the ability of these cells to form tumours in nude mice
(Iliopoulos et al. 1995). Thus, VHL was  shown to  act  as  a  tumour  suppressor  gene,
although the mechanism of action was still not known.
As many of the tumours associated with VHL were highly vascular, and as a
rare paraneoplastic phenomenon, some patients affected with these tumours suffered
from erythrocytosis due to overproduction of erythropoietin (EPO), a link between
oxygen sensing and VHL-related tumours was hypothesised (Kim and Kaelin 2004).
Further studies indeed corroborated this, as VHL negative cells were shown to over-
express the vascular endothelial growth factor (VEGF), glucose transporter GLUT1,
and platelet-derived growth factor (PDGF) mRNAs, even in normoxic conditions
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(Iliopoulos et al. 1996). This function was dependent on pVHL forming a complex
with Cul2, Elongin B, and Elongin C (Lonergan et al. 1998), which provided
important clues into the function of pVHL, as the other members of the complex were
homologous to yeast proteins involved in ubiquitin-mediated proteolysis. Thus, a role
for VHL in ubiquitin-mediated degradation of proteins was proposed, which lead to
the  questions  about  the  targets  of  this  complex,  and  whether  these  targets  could  tell
something about the link between VHL and hypoxia signalling.
Around the same time, another line of research had identified a novel
transcription factor called hypoxia-inducible factor (HIF) through its activity to
induce EPO expression (Semenza 1998). This factor had been shown to act as a
heterodimer consisting of HIF1  and HIF1  subunits; HIF1  was stably expressed,
but the HIF1  level was rapidly induced in hypoxia. Thus the question arose: Could
HIF be the missing link between VHL and hypoxia? Evidence in favour of this idea
soon  came  from  the  work  of  Maxwell  et  al.  (1999)  who  showed  that  pVHL  had  a
critical role in the oxygen-dependent degradation of HIF1 . The mechanism by which
pVHL directs HIF1  for degradation was shown to be by recruiting the substrate to a
ubiquitination machine (Ohh et al. 2000), which provided a mechanism for the pVHL-
HIF1  interaction, although the basis for the oxygen-dependency of this reaction was
not clear. Soon after though, two groups showed that an oxygen-dependent post-
translational modification, namely the hydroxylation of specific prolyl residues of
HIF1  was necessary for its degradation (Ivan et al. 2001, Jaakkola et al. 2001), and
further studies on model organisms led to the identification of the HIF prolyl
hydroxylase genes which in an oxygen-dependent manner hydroxylated these critical
prolyls in HIF1  (Epstein et al. 2001). Although these studies provided mechanistic
evidence linking VHL to hypoxia signalling, it was still not clear whether the same
mechanism was responsible for tumour suppression.
Further evidence to support the role of pVHL in RCC formation came from a
study that showed loss of VHL and induction of HIF-1 already in the early lesions of
the kidney (Mandriota et al. 2002). By studying the tumour formation in nude mice,
Kondo et al. (2002) reported that the ability of the 786-O cells to form tumours after
reintroduction of VHL was rescued by expressing a HIF2 -mutant that was
insensitive to prolyl hydroxylation, and thus to oxygen-dependent degradation. This
suggested that HIF was indeed necessary for tumour formation. Furthermore, the
same group showed that the down-regulation of HIF2  in VHL null cells was
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sufficient to suppress tumour formation in vivo (Kondo et al. 2003). Together these
studies showed that HIF2  was a critical down-stream factor of pVHL in renal
tumorigenesis.
The VHL syndrome can be devided phenotypically into 2 different types
according to the presence or absence of phaeochromocytoma (Maher and Eng 2002).
Type 1 mutations, which normally result in total or partial VHL loss or improper
folding, result in hemagioblastomas and RCC, but not phaeochromocytomas. Type 2a
mutations result in hemangioblastomas and phaeochromocytomas with a low risk of
RCC, while type 2b mutations have the same tumour spectrum as 2a but with an
increased risk of RCC, and type 2c mutations predispose only to
phaeochromocytomas. There is a genotype-phenotype correlation suggesting that
complete loss of pVHL function would not result in phaeochormocytoma
development. Moreover, genetic evidence shows that the VHL gene  is  lost  either  by
somatic mutations or silencing by hypermethylation in about 30% of sporadic
hemagioblastomas (Kim and Kaelin 2004) and in 50% of clear-cell RCCs (Gnarra et
al. 1994, Herman et al. 1994, Kim and Kaelin 2004, Whaley et al. 1994), but truly
somatic VHL mutations in phaeochromocytomas have not been detected (Neumann et
al. 2002). Also, mutations in other tumour types are rare (Gnarra et al. 1994, Whaley
et al. 1994). Furthermore, functional analyses of different VHL mutation types have
suggested that type 2c mutations do not lead to over-expression of hypoxia inducible
genes (Clifford et al. 2001, Hoffman et al. 2001). All this evidence supports the role
of VHL as a classical tumour suppressor gene of the Knudson’s two-hit hypothesis
type in haemangioblastomas and RCC, but not in phaeochromocyotoma. This
suggests that phaeochromocytoma development might require mutations in many
cells (a field effect), or that the mutations would have to be present within a very
specific time-window (Kim and Kaelin 2004). Evidence favouring the latter
explanation has emerged recently, suggesting a role for VHL in neuronal apoptosis
and developmental culling (Lee et al. 2005).
Together all these data on the tumour suppressor VHL highlight several
characteristic features of the current tumour suppression paradigm (Sherr 2004).
Firstly, inherited mutations in VHL predispose to a tumour syndrome which is
transmitted in an autosomal dominant manner. Also, the sporadic counterparts of
VHL associated tumours, at least RCC and haemangioblastoma, harbour mutations in
the same gene. This is a great example of how the study of rare inherited syndromes
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can tell a great deal about the genetic basis of common tumours. Secondly, both
classes of tumours, sporadic and familial, show loss of the wild-type allele indicating
that VHL acts recessively at the cellular level, which is a classical feature of a tumour
suppressor gene. Thirdly, VHL seems to function as a gatekeeper for tumour
initiation, which highlights its important role in early tumorigenesis. Fourthly, a
genotype-phenotype correlation between different mutations and the clinical
manifestations of the disease show that there is inherent logic in the pathobiology of
these tumours. The functional studies have been able to dissect the rules behind these
differences providing insight into the tissue specificity of tumours, a fundamental
question of modern cancer research. Lastly, the discoveries on VHL function provides
a beautiful example of how seemingly simple clinical observation can be combined
with scientific outlook to bring new insight into our knowledge on common diseases,
and how this knowledge can be further utilised for the benefit of patients in the form
of more rationally developed targeted therapies.
2.4  Hereditary leiomyomatosis and renal cell cancer (HLRCC)
The syndrome hereditary leiomyomatosis and renal cell cancer (HLRCC) was first
described in 2001 (Launonen et al.). The first hint of a new syndrome came from a
patient that had been referred to genetic counselling due to apparent familial
clustering of renal cell cancer in her family. Further studies of the medical records
revealed that the RCCs were of a rare histological type, papillary type 2, and that
uterine and cutaneous leiomyomas were also associated with the phenotype. In the
course  of  the  study,  another  family  with  the  same  type  of  RCC  was  identified,  and
subsequently a genetic linkage analysis mapped the disease locus to chromosome
1q42-q44. Several tumours showed loss of the unlinked chromosome, further
supporting the involvement of 1q in the disease predisposition. In addition to
leiomyomas  and  RCC,  the  affected  females  seemed  to  have  an  increased  risk  of
leiomyosarcoma (Launonen et al. 2001). Soon after, another group published the
localisation of a gene predisposing to multiple cutaneous and uterine leiomyomata
(MCUL) to the same 1q42.3-q43 chromosomal region as HLRCC (Alam et al. 2001).
These patients suffered from multiple cutaneous leiomyomas and uterine fibroids, but
no predisposition to malignant tumours was observed in the 11 families studied. It
was immediately suspected that HLRCC and MCUL were phenotypic variants of the
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same syndrome, and evidence to support this was soon published as a family
diagnosed with multiple cutaneous leiomyomatosis was found to be compatible with
linkage to the 1q predisposition locus (Kiuru et al. 2001). Also, individuals in the
family were found to be affected by RCC and leiomyosarcoma, further strengthening
the link between MCUL and HLRCC. The cutaneous lesions were found to show
LOH at 1q establishing the syndrome as a two-hit condition following Kundson’s
hypothesis (Knudson 1971). The MCUL and HLRCC teams joined for The Multiple
Leiomyoma Consortium which in a short time identified the responsible gene,
fumarate hydratase (FH) (Tomlinson et al. 2002). The consortium showed that in
addition to having germline mutations, the FH enzyme activity was reduced in the
lymphoblastoid cell lines from the carriers and the cutaneous tumours from these
individuals showed very low or absent FH enzyme activity. Additional families with
germline FH mutations displaying the HLRCC phenotype were later also published in
North America (Toro et al. 2003). Screens for mutations and LOH in 1q showed that
somatic inactivation of FH was rare in the sporadic counterparts of HLRCC
associated tumours, although some 1q LOH was observed in uterine fibroids (Barker
et al. 2002) and one soft tissue sarcoma with a somatic mutation and loss of the wild-
type FH was found (Kiuru et al. 2002).
Fumarate hydratase (FH, fumarase) is an enzyme catalysing the hydration of
fumarate to form malate in the Krebs tricarboxylic acid cycle (TCAC) in
mitochondria (Stryer 1995). The functional enzyme is a homotetramer (Weaver et al.
1995) which is encoded by a nuclear gene (Tolley and Craig 1975). Both
mitochondrial and cytosolic forms of FH exist (Edwards and Hopkinson 1979a, and
1979b). Homozygous mutations of FH result in the recessive disorder fumarase
deficiency which manifests in severe developmental disorder with neurological and
muscular involvement (Bourgeron et al. 1994, Gellera et al. 1990, Rustin et al. 1997).
The involvement of a housekeeping gene like FH in tumour predisposition was a
surprise, and several hypotheses for the tumorigenic mechanism were suggested, such
as superoxide overproduction (Rustin 2002) or oxidative stress, pseudo-hypoxic drive,
defect in apoptosis due to mitochondrial dysfunction, and anabolic drive (Eng et al.
2003, Pollard et al. 2003). Genotype-phenotype correlation for different
manifestations of FH mutations regarding FH deficiency, MCUL and HLRCC could
not be detected. Functional analysis showed loss or clear reduction of the enzyme
28
activity in all these syndromes therefore suggesting that all known FH mutations had
very similar functional effects (Alam et al. 2003).
2.5  Other hereditary forms of RCC
Based on histological and genetic data, RCCs have been classified into distinct
subtypes. These classes are: conventional (clear-cell); papillary, of which two distinct
subtypes exist (types I and II); chromophobe; oncocytoma; collecting duct; and
unclassified (Kovacs et al. 1997). The conventional and papillary RCCs are thought to
arise from the epithelial  cells  of the proximal part  of the renal tubule (Bodmer et  al.
2002) whereas chromophobe, oncocytoma, and collecting duct tumours arise from the
collecting duct cells (Bodmer et al. 2002, Cohen and McGovern 2005). As discussed
above, the role of VHL in familial clear-cell RCC is well characterised (Bodmer et al.
2002, Cohen and McGovern 2005). In addition, constitutional translocations
involving chromosome 3 have been shown to segregate with the conventional RCC
phenotype, although the responsible genes have not as yet been identified (Bodmer et
al. 2002).
Familial papillary RCC is caused by germline mutations in the MET proto-
oncogene which is a transmembrane receptor tyrosine kinase that normally responds
to the hepatocyte growth factor (Schmidt et al. 1997). These tumours are of papillary
type I histology and seem to have a better prognosis than the type II tumours (Cohen
and McGovern 2005). In contrary to classical tumour predisposition syndromes, the
mutations in the MET kinase domain are of an activating nature, leading to ligand-
independent growth promoting signalling (Jeffers et al. 1997). Instead of
chromosomal deletions, amplification of the mutated allele occurs in tumours,
multiplying the growth promoting signalling (Zhuang et al. 1998).
A rare autosomal dominant tumour predisposition syndrome, Birt-Hogg-Dubé
syndrome (BHD), which is characterised by hair-follicle hamartomas of the face and
neck, manifests in about 15% of cases also as renal tumours (Cohen and McGovern
2005). The renal lesions are typically chromophobe or mixed chromophobe-
oncocytoma tumours, although papillary and clear-cell RCCs have also been detected
in these patients (Schmidt 2004). The gene underlying the syndrome, BHD, has
recently been identified (Nickerson et al. 2002) and it is suspected to act as a tumour
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suppressor, as a second hit has been detected in several renal BHD tumours (Vocke et
al. 2005). Mutations in sporadic tumours are detected only rarely (Schmidt 2004). The
function of the BHD gene product, folliculin, is not known, although it is
evolutionarily conserved (Nickerson et al. 2002). As both proximal and distal tubule
tumours are associated with BHD, it has been suggested that folliculin regulates an
early cell that still has the potency to differentiate into both proximal and distal tubule
cells. Two animal models carrying germline mutations in the orthologous BHD genes
have been described, both developing renal tumours (Lingaas et al. 2003, Okimoto et
al. 2004).
Hyperparathyroidism-jaw tumour (HPT-JT) syndrome is an autosomal
dominant multiple neoplasia condition characterised by hyperparatyreoidism caused
by parathyroid tumours. Other manifestations are ossifying fibromas, most commonly
affecting the mandible and maxilla (Jackson et al. 1990). Also, patients seem to have
an increased risk of renal neoplasms, namely adult Wilms tumours, mixed epithelial-
stromal  tumours,  multiple  renal  cysts,  and  sometimes  also  papillary  renal  cell
carcinoma (Tan and Teh 2004). Interestingly, HPR-JT is associated with various
uterine lesions such as adenosarcomas, adenofibromas, leiomyomas, adenomyosis,
and endometrial hyperplasia (Bradley et al. 2005). Germline mutations in the HRPT2
gene were recently identified in several HPR-JT families, and inactivating mutations
were also detected in some sporadic parathyroid adenomas (Carpten et al. 2002). The
inactivating nature of the mutations, together with results showing chromosomal
somatic  LOH  at  the HRPT2 locus, indicate that the HRPT2 product, parafibromin,
might function as a tumour suppressor. Parfibromin is an evolutionarily conserved
protein that is ubiquitously expressed (Carpten et al. 2002), and recent evidence
shows that it may have a function regulating the Wnt-signalling pathway (Mosimann
et al. 2006).
Tuberous sclerosis complex is an autosomal dominant syndrome predisposing
to infantile seizures, mental retardation, autism, and tumours in the brain, retina,
kidneys, heart, and skin (Astrinidis and Henske 2005). The renal manifestations are
wide ranging including benign angiomyolipomas, which are composed of abnormal
vessels, immature smooth muscle cells and fat cells, multiple renal cysts,
oncocytomas, and renal cell carcinomas of clear-cell, papillary, and chromophobe
histologies (Henske 2004). Tuberous sclerosis complex is caused by mutations in
either TSC1 (The European Chromosome 16 Tuberous Sclerosis Consortium 1993) or
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TSC2 (van Slegtenhorst et al. 1997), which encode proteins hamartin and tuberin,
respectively. They have been shown to interact and the complex has a well
characterised function in modulating the mTOR signalling pathway (Wullschleger et
al. 2006). That the renal tumours associated with TSC can be of both mesenchymal
and epithelial origin has lead to the idea that tuberin and hamartin might be regulators
of the early progenitor cells in the kidney (Henske 2004). The Eker rat, which
harbours a germline mutation in the rat homologue of TSC2, has a phenotype of both
renal cell carcinomas and uterine leiomyomas (Cook and Walker 2004).
2.6  Uterine leiomyomas
Uterine leiomyomas (also called fibroids or myomas) are benign tumours arising
within the smooth muscle lining of the uterus, the myometrium. They are thought to
originate from smooth muscle cells. Although benign, they cause significant
morbidity in the form of abdominal pain, abnormal bleeding, and even infertility
(Stewart 2001). Fibroids are the single most common cause for hysterectomies
accounting for about 50% of these operations in Finland (Luoto et al. 1994).
Therefore, fibroids represent a major burden on the health care system. Uterine
fibroids are very common, affecting up to 77% of women (Cramer and Patel 1990),
although clinically symptomatic fibroids are significantly less frequent (Stewart
2001).
Even though fibroids are very common, not much is known about their
aetiology. Several risk factors have been detected in epidemiological studies. Early
menarche, age, obesity, and the intake of red meat have been proposed as risk factors,
whereas parity, smoking, and exercise have been shown to inversely correlate with the
incidence of fibroids (Flake et al. 2003). A common denominator for all these risk
factors might be oestrogen metabolism and, accordingly, oral contraceptives, hormone
replacement therapy, and treatment with tamoxifen, a partial oestrogen agonist, have
been shown to have effects on fibroids (Flake et al. 2003). However, different studies
have contradicting results, and the exact role of oestrogens in fibroid development is
not clear. Generally it is thought that these tumours are oestrogen dependent and that
hormone replacement therapy, for example, would inhibit normal shrinkage of
fibroids after menopause. Evidence supports this notion (Polatti et al. 2000). On the
other hand, tamoxifen therapy seems to have growth promoting effects on fibroids
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(Dilts et al. 1992), although in vitro studies have shown that it inhibits the growth of
oestrogen stimulated growth of Eker rat derived uterine cell lines (Fuchs-Young et al.
1996).
Several lines of evidence suggest that genetic factors seem to have an impact
on fibroid development. Firstly, from epidemiological studies there is evidence that
the prevalence of fibroids is higher among black than white women (Flake et al.
2003). Also, studies on twins have shown a greater concordance for hysterectomy
(Treloar et al. 1992) and hospitalisation due to uterine fibroids (Luoto et al. 2000) in
monozygotic  than  dizygotic  twins,  and  based  on  the  recurrence  rate  in  siblings,  the
heritability of fibroids has been estimated to be between 0.26 and 0.80 (Kurbanova et
al. 1989, Luoto et al. 2000, Snieder et al. 1998). Although a rare example, HLRCC
also represents evidence for the genetic predisposition to fibroids, and similar
mechanisms could be involved in sporadic fibroid formation as well. Similarly, Alport
syndrome, a rare condition which is sometimes associated with diffuse
leiomyomatosis of the oesophagus, tracheobronchial, and genitourinary tract, is
inherited in a dominant X-linked manner (Miner 1999). It is caused by germline
deletions in collagen IV genes (Zhou et al. 1993), which could indicate a more
widespread role of these extracellular proteins in common fibroids.
The clonality of uterine fibroids has been studied by methods that rely on the
random inactivation of the X chromosomes during development. If a tumour is of
clonal origin, the same X chromosome should be inactivated in all the cells, whereas
if the origin of tumour is polyclonal, it should have developed from a heterogeneous
group of cells in which some cells have inactivated one of the copies and others have
inactivated the other copy (Fearon et al. 1987). The first report indicating that fibroids
are clonal was published in 1965 (Linder and Gartler 1965) and several subsequent
studies have confirmed these findings (Hashimoto et al. 1995, Mashal et al. 1994). In
addition, as both karyotypically normal and abnormal cells have been shown to have
similar X-chromosome inactivation pattern in individual tumours, it has been
suggested that clonal expansion occurred before karyotypic changes (Mashal et al.
1994, Xing et al. 1997). Fibroids from the same patient have commonly different
inactivated X-chromosomes suggesting independent development of multiple tumours
instead of dissemination of only one tumour clone (Hashimoto et al. 1995, Linder and
Gartler 1965, Mashal et al. 1994). Thus, the evidence shows that fibroids develop
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through clonal expansion of one individual cell clone instead of a field effect, such as
abnormal hormone secretion.
Traditionally, chromosomal changes in fibroids have been studied by
cytogenetic methods. About 40-50% of fibroids show chromosomal (karyotypic,
cytogenetic) changes, some of which are non-random (Sandberg 2005). The most
common changes are t(12;14)(q15;q23~q24), del(7)(q22q23), rearrangements
involving 6p21 and 10q, trisomy 12, and deletions of 3q. Fibroids with karyotypic
abnormalities are larger than karyotypically normal fibroids, and also, fibroids
carrying t(12;14) tend to be the larger and those carrying del(7) (Rein et al. 1998).
The most common change is t(12;14)(q15;q23~q24) occurring in about 20%
of karyotypically abnormal fibroids. These regions are therefore thought to play a role
in the pathogenesis of fibroids. The 12q15 region harbours a high mobility group
protein encoding gene, HMGA2,  which together with another protein from the same
family, HMGA1, have higher expression in uterine fibroids compared to normal
myometrium (Klotzbucher et al. 1999). Further studies on fibroids have identified
aberrant HMGA2 splice variants (Ingraham et al. 1999, Kurose et al. 2001,
Schoenmakers et al. 1995) and fusion transcripts involving various other genes on
different chromosomes such as ALDH2 (Kazmierczak et al. 1995), RAD51L1
(Schoenmakers et al. 1999, Takahashi et al. 2001), COX6C (Kurose et al. 2000), and
HEI10 (Mine et al. 2001). Later it has been postulated that the dysegulated HMGA2
expression, rather than aberrant fusion transcripts, would be of importance in fibroid
development (Quade et al. 2003). HMGA1, on the other hand, is located at 6p21, a
region which also shows recurrent changes in fibroids (Sandberg 2005). A study on
the Eker rat showed HMGA2 expression also in murine tuberin-deficient fibroids.
Taken together, these observations suggest that the HMG-proteins could have a role
in leiomyomagenesis, although direct functional evidence of this is still lacking.
Recurrent interstitial deletions of chromosome 7q ranging from q11.23 to q36
were originally detected in cytogenetic studies (Sandberg 2005), and subsequently a
number of molecular allelotyping studies have further characterised these changes
(Ishwad et al. 1995, Ishwad et al. 1997, Mao et al. 1999, Sell et al. 1998, van der
Heijden et al. 1998). The studies have pointed to a commonly deleted region within
the chromosome region 7q22-q31 (Figure 2), but although several genes from this
region have been proposed as having a role in leiomyomagenesis, no robust genetic
evidence for this has been produced. Despite some mutation screening efforts (Barker
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et al. 2002, Patrikis et al. 2003), the only point mutations in fibroids reported before
this  study,  in  addition  to  those  associated  with  HLRCC,  were  3  cases  of KRAS
mutations (Hall et al. 1997).
Marker d7s657 d7s491 d7s515 d7s518 d7s2453 d7s501 d7s496 d7s692 d7s471
Bp on Chr 7. 92644141 96333815 101490508 101648945 105445157 106227728 106941949 108126945 111824676
Ischwad. et al 1995
Ischwad et al. 1997
Sell et al 1998
van der Heijden et al. 1998
Mao et al. 1999
Figure 2. Minimal chromosome 7q21.3-q31.1 deleted regions detected in previous allelotyping studies
on uterine fibroids.
The global gene expression pattern in uterine fibroids has been studied
previously on several different platforms (Ahn et al. 2003, Arslan et al. 2005,
Catherino et al. 2003, Chegini et al. 2003, Hoffman et al. 2004, Quade et al. 2004,
Skubitz and Skubitz 2003, Tsibris et al. 2002, Wang et al. 2003, Weston et al. 2003),
and great expectations have been laid on the genome-wide approach on uterine fibroid
biology (Freije 2003). Some commonly deregulated genes have been identified,
although the results from different experiments are largely non-overlapping (Arslan et
al. 2005). The variation is likely due to the wide range of expression microarray and
data analysis methods utilised in these studies (Hoffman et al. 2004, Tsibris et al.
2003). The small number of samples has compromised the statistical power of several
of these studies and, also, none of them have taken into account different genetic
statuses of the tumours.
2.7  Familial paraganglioma
Paragangliomas are tumours of the neurogenic origin, and they arise within the
paraganglia that are dispersed throughout the body (Baysal 2002). The
paragangliomas  in  the  head  and  neck  (HNP)  regions  are  associated  with  the
parasympathetic nervous system and are normally hormonally silent. The most
common site  of  HNPs is  the  carotid  body,  although they  are  more  than  20  different
locations where they can occur. Paragangliomas arising below the neck,
phaeochromocytomas, on the other hand, are more closely associated with the
sympathetic nervous system, and they often give symptoms, such as hypertensive
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crises, due to catecholamine secretion. The most common location of
phaeochromocytomas is within the adrenal gland (Baysal 2002).
The first locus (PGL1) for hereditary paragangliomas (HPGL) was mapped by
classical linkage analysis to chromosome 11q23-qter, and the pattern of inheritance
suggested genomic imprinting as affected females did not transmit the disease
(Heutink et al. 1992). Subsequent studies showed that LOH is not common in
paragangliomas, apart from chromosome 11 which is lost in the chief cell
compartment of these tumours (Devilee et al. 1994, van Schothorst et al. 1998). This
suggested that PGL1 was a tumour suppressor gene, and that chief cells formed the
neoplastic component of the tumours. After extensive fine mapping efforts (Baysal et
al. 1999, van Schothorst et al. 1996), the PGL1 gene was identified later as SDHD and
it was the first nuclear encoded mitochondrial gene to be linked to neoplasia (Baysal
et al. 2000). The mutations were predicted to be truncating in most of the cases. A
strong founder effect has also been detected in Dutch PGL1 families, as most patients
have been shown to be affected by only a few mutations (Taschner et al. 2001, van
Schothorst et al. 1998). As phaeochromocytomas and paragangliomas were known to
be  related,  it  was  no  great  surprise  when SDHD mutations were detected also in
patients and families with phaeochromocytoma (Gimm et al. 2000).
Subsequent studies investigated the role of the other genes encoding SDH in
patients with paraganglioma or phaeochromocytoma. Mutations in SDHC (PGL3)
were mapped (Niemann et al. 2001) to chromosome 1q21-q23 and identified
(Niemann and Muller 2000) in a single German family, and SDHB (PGL4) mutations
on chromosome 1p36 were detected by candidate gene screening (Astuti et al. 2001).
One additional locus, PGL2, has been mapped to chromosome 11q12-q14 (Mariman
et al. 1993), but the responsible gene has not been identified. In contrast to SDHB,
SDHC, and SDHD, no mutations in the fourth SDH gene, SDHA, have been detected
in tumours, but homozygous mutations in SDHA result in Leigh syndrome (Bourgeron
et al. 1995), a severe developmental disorder similar to FH deficiency. There are
several possible explanations as to why SDHA mutations do not predispose to cancer.
The discovery of a second gene encoding SDHA (Tomitsuka et al. 2003), if proven to
be functional, would make it plausible to speculate that in order to develop full SDHA
deficiency, 4 hits would be required, which is highly unlikely (Gottlieb and
Tomlinson 2005).
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Most HPGL tumours seem to have a second hit, suggesting that the SDH
genes are tumour suppressors (Gottlieb and Tomlinson 2005). In the case of SDHB
and SDHC, the wild-type allele is normally lost by a deletion. SDHD, on the other
hand, was first thought to be imprinted (Heutink et al. 1992) but further studies have
shown biallelic expression of SDHD in several tissues (Baysal et al. 2000). It has
therefore been proposed that the imprinted gene/genes are only linked to SDHD,
which is supported by the observations that the whole maternal chromosome 11 seems
to be lost in PGL1 tumours (Hensen et al. 2004). Thus, the chromosomal deletion of
the maternal wild-type SDHD would  also  result  in  the  loss  of  another,  maternally
expressed tumour suppressor.
The SDH complex is formed by 4 different subunits. SDHC and SDHD are anchor
proteins that connect the holoenzyme to the mitochondrial membrane. SDHA, the
flavoprotein, and SDHB, the iron-sulphur protein, form the catalytic domain
(Yankovskaya et al. 2003). SDH takes part in two different metabolic pathways, the
Krebs cycle and the electron transport chain, in which it forms the mitochondrial
complex II. There are 5 mitochondrial complexes; complexes I to IV function as
electron  transporters  and  complex  V  as  a  ATP  synthase  (Eng  et  al.  2003).  No
mutations in tumours have been detected in the genes encoding the mitochondrial
complexes other than complex II, but defects in these complexes can result in
developmental disorders (Eng et al. 2003). Therefore, SDH defects could be predicted
to result in a different phenotype than mutations in FH, which does not function in the
electron transport.
Carriers of SDHB mutations seem to have an increased risk of adrenal
phaeochromocytoma and lower risk of paraganglioma compared with patients having
mutations in SDHD (Neumann et al. 2004, Pawlu et al. 2005). Mutations in SDHD
seem to increase the risk of multifocal tumours, and SDHB mutations that of
malignant extra-adrenal paragangliomas (Gimenez-Roqueplo et al. 2003). SDHB
mutations are more likely to abrogate SDH function in the TCA cycle than mutations
in SDHD,  which  could  explain  some  of  the  phenotypic  differences.  However,  if  all
SDH mutations result in complete loss of SDH function, as has been suggested, these
differences are hard to explain (Gottlieb and Tomlinson 2005). SDHC mutations are
rarer and they seem to cause a benign phenotype (Schiavi et al. 2005).
 Other syndromes that include predisposition to phaeochromocytomas or
paragangliomas are VHL (discussed above), multiple endocrine neoplasia type 2
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(MEN2), and neurofibromatosis 1 (NF1) (Maher and Eng 2002). MEN2 is caused by
germline mutations in the RET proto-oncogene, and it can be divided into 3 clinically
distinct subtypes: MEN2A, MEN2B, and familial medullary thyroid carcinoma
(FMTC). MEN2A, which is the most common subtype, is characterised by medullary
thyroid carcinoma, phaeochromocytoma and hyperparathyroidism. MEN2B has the
same tumour spectrum as MEN2A, but the symptoms start about 10 years earlier. The
last form, FMTC, is characterised by MTC only. RET mutations have been detected in
about 95% of MEN2 cases. There is a genotype-phenotype correlation between the 3
different forms of MEN2 and the position of the mutation, although some overlap has
been detected. Altogether, about 50% of MEN2 patients develop
phaeochromocytoma. NF1 is caused by germline mutations in the NF1 tumour
suppressor, and the risk of phaeochromocytoma in these patients is between 0.1% and
5.7% (Opocher et al. 2005).
2.8  From mitochondrial dysfunction to neoplasia
Mutations in genes encoding two nuclear encoded mitochondrial enzymes, FH and
SDH, have been implicated in cancer. SDH functions in the TCA cycle and converts
succinate into fumarate, and FH continues from there, converting fumarate into
malate. Therefore, the TCA cycle appears as a natural denominator for both FH- and
SDH-associated  neoplasia  syndromes.  However,  SDH  also  has  a  role  in  the
mitochondrial electron transport chain. As described above, the tumour spectra of
these mutations do not overlap, which clearly indicates that the tumorigenic
mechanisms cannot be identical. Still, several hypotheses have been proposed that try
to link both the mitochondrial dysfunction and the biology of these two syndromes to
tumorigenesis. These theories include a decrease in apoptosis, an increase in the
production of reactive oxygen species (ROS), and the activation of hypoxia signalling
under normoxic conditions (pseudo-hypoxia) (Eng et al. 2003, Gottlieb and
Tomlinson 2005, Pollard et al. 2003).
It is well established that mitochondria have an essential role in apoptosis
(Hengartner 2000), and that mitochondrial metabolims and apoptotic mechanisms are
linked (Downward 2003). Therefore, it seems plausible that defects in mitochondrial
metabolic enzymes could lead to defects in apoptosis. Indeed, there is some evidence
that mutations in SDHC could inhibit cellular responses to various apoptotic signals
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(Albayrak et al. 2003). Also, downregulating SDHD has been shown to protect cells
from apoptosis (Lee et al. 2005). Still it is not clear whether the blockage of the TCA
cycle and/or the electron transport chain would always lead to a decrease in apoptosis,
and alternative hypotheses have to be kept in mind (Gottlieb and Tomlinson 2005).
Increased ROS production has also been detected in SDH-deficient cells
(Albayrak et al. 2003, Ishii et al. 2005). This is mainly thought to result from the
disruption  of  the  electron  transport  chain,  and  not  from  the  blockage  of  TCA  cycle
and, therefore, FH mutations are not predicted to result in increased amounts of ROS.
It has been postulated that a mild increase in ROS could be beneficial for tumours
(Rustin 2002). Oxidative damage could also cause mutations in nuclear DNA, some
of which could be important for tumorigenesis (Gottlieb and Tomlinson 2005).
Another link from ROS to tumorigenesis could be through the induction of HIF
signalling. There is evidence that ROS can activate HIF by inhibiting HIF prolyl
hydroxylases (Gerald et al. 2004). The activation of HIF, on the other hand, can have
several beneficial effects on a tumour cell, such as increased aerobic glycolysis
(Gatenby and Gillies 2004). The activation of HIF in SDH- and FH-deficient cells can
also be achieved through a mechanism independent of ROS. Recent results have
shown that blocking FH or SDH activity results in the accumulation of fumarate and
succinate, respectively, and they both can inhibit HIF prolyl hydroxylation (Isaacs et
al. 2005, Selak et al. 2005). In this model, succinate and fumarate act as internal




The following 4 hypotheses form the basis of this work:
H1)  A subset of early-onset renal cell carcinomas (RCC) is caused by HLRCC
H2)  Chromosome 7q21-31 harbours a leiomyoma suppressor gene
H3)  Uterine leiomyomas carrying a 7q-deletion form a biologically distinct
subgroup of leiomyomas




4.1  LOH mapping and genomic sequencing (I, II, III, IV)
Both loss of heterozygosity (LOH) mapping and genomic sequencing rely
fundamentally on the polymerase chain reaction (PCR), which enables exponential
amplification of the target sequence. This cyclic method of enzymatic amplification of
DNA in vitro was originally introduced in 1985 (Saiki et al. 1985). In the beginning,
thermolabile Klenow fragment of Escherichia coli DNA  polymerase  I  was  used  to
catalyse the extension reaction of the primers, but only the introduction of the DNA
polymerase from the thermophilic bacterium Thermus aquaticus (Taq) facilitated
wider use of PCR (Saiki et al. 1988). This development greatly simplified the
procedure as no longer was it necessary to add more enzyme after each denaturation
step.  Also,  due  to  higher  extension  temperatures,  the  reaction  became more  specific
and efficient, making sequencing of various and even closely homologous target
sequences possible (Saiki et al. 1988).
LOH or, more precisely, allelic imbalance (AI), is measured by comparing the
amount of PCR products amplified from the two constitutional chromosomes. This is
possible when the sequence amplified contains a polymorphism that distinguishes
between the two alleles. Typically, the polymorphic sequences that are utilised for
LOH mapping are microsatellite repeats although, for example, single nucleotide
polymorphisms can be used for this as well. Microsatellites are short tandem repeats
of very simple DNA sequences, usually 1-4 bp long, for example (GT)n,  that  are
widely dispersed throughout the genome. Probably because of their repetitive
structure, they are prone to replication errors and unequal crossover, and therefore
they are usually highly polymorphic (Strachan and Read 1999). Mononucleotide
repeats are usually very polymorphic, but they are also prone to replication errors
during the PCR. Therefore, di- tri- and tetranucleotide repeats are commonly used
when assessing LOH.
We wanted to analyse uterine leiomyomas for LOH at two regions of interest,
chromosome 1q43, the region where FH is located, and 7q21-q31, which is
commonly deleted in uterine leiomyomas. For 7q we identified 25 microsatellite
markers covering the whole region that according to previous reports harbours the
minimal deleted region. For 1q, only two markers flanking the FH locus were utilised,
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as the assumed target, the FH gene,  was  already  known.  The  markers  were  chosen
utilising the Ensembl genome browser (www.ensembl.org) (Birney et al. 2006) that
contains marker information from various genetic maps, such as Marshfield (Broman
et al. 1998) and Genethon (Gyapay et al. 1994). When no previously described
markers where available, the genomic target region was searched for microsatellite
repeats by Tandem repeats finder (Benson 1999) and PCR primers were designed by
the Primer3 program (Rozen and Skaletsky 2000). Fluorescence-labelled primers
(Sigma-Genosys, Cambridgehire, UK) were used to amplify matching normal and
tumour DNA with PCR. The PCR products were detected with the ABI377 sequencer
and analysed with Genotyper 2.5.2 software (Applied Biosystems, Foster City, CA).
LOH was scored by calculating the intensity ratio of the constitutional alleles as
described before (Canzian et al. 1996). Intensity ratio L < 0.60 or L > 1.67 was called
LOH, 0.60 < L < 0.75 or 1.33 < L < 1.67 was called marginal LOH and 0.75  L 
1.33 was called normal heterozygosity.
For genomic sequencing we utilised a method based on the combination of
Sanger sequencing (Sanger et al. 1977) and fluorescence detection (Prober et al. 1987,
Smith et al. 1986). Over the years, this approach has become more efficient through
‘evolutionary’ advancements (Metzker 2005), and its power has been proved by the
success  of  the  Human  Genome  Project  (Collins  et  al.  2003,  International  Human
Genome Sequencing Consortium 2004, Lander et al. 2001).
For the leiomyoma candidate gene screening on 7q, gene information was
obtained from Ensembl (Birney et al. 2006) and UCSC (Kent et al. 2002) genome
browsers. Genomic PCR primers for all known manually annotated protein coding
genes (Ashurst et al. 2005) within the minimal deleted region were designed utilising
the Primer3 program (Rozen and Skaletsky 2000). The primers were designed to
amplify  coding  exons  and  the  flanking  splice  site  junctions.  The  PCRs were  carried
out in a 25 or 50 µl reaction volume containing 50 or 100 ng of genomic DNA,
respectively, 1x PCR buffer (Applied Biosystems, Branchburg, NJ,  USA),  300  µM
each deoxynucleotide triphosphate (dNTP) (Finnzymes, Espoo, Finland), 1 µM
forward and reverse primer (Sigma-Genosys, Cambridgehire, UK), 1.25 or 2.5 units
of AmpliTaq Gold polymerase, (Applied Biosystems), respectively, and 1.5 to 3 mM
MgCl2. The general cycling conditions were as follows: 10 min at 95°C; followed by
35 cycles of denaturation at 95°C for 45 s, annealing at 55 to 62°C for 1 min,
elongation at 72°C for 1 min, and a final extension at 72°C for 10 min. A 5 µl aliquot
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of the PCR product was run on an agarose gel to verify the specificity of the reaction,
and the rest of the product was purified using the NucleoSpin PCR purification kit
(Macherey-Nagel, Düren, Germany) or by ExoSAP-IT (USB, Cleveland, Ohio, USA).
Direct sequencing of PCR products was performed using Applied Biosystems 3100
and 3730 BD3.1 sequencing chemistry and 5.1 sequencing analysis software (Applied
Biosystems). The mutation screening of FH and  all  4  genes  coding  the  subunits  of
SDH, SDHA, SDHB, SDHC, and SDHD was essentially performed as outlined above.
The primer sequences for each gene were obtained from literature (Astuti et al. 2001,
Baysal et al. 2000, Kiuru et al. 2002), except for SDHA,  for  which  primers  were
designed.
4.2 Microarray comparative genomic hybridisation (II, IV)
In addition to LOH mapping, microarray comparative genomic hybridisation (aCGH)
was performed to further characterise the changes observed in uterine leiomyomas.
The aCGH method is based on simultaneous hybridisation of differentially labelled
tumour and normal DNA on microarray chips that contain short fragments of DNA as
probes.  We performed two different  aCGH experiments.  The  first  array  contained  3
452 large genomic bacterial artificial chromosome (BAC) DNA clones at an average
spacing of about 1 Mb throughout the genome. The second array was produced from
two separate sets of BAC DNA clones; the first set consisted of 573 clones selected
from  the  array  of  3452  clones  used  in  the  1  Mb  resolution  array,  and  a  second  set
consisted of 1083 clones from chromosome 7q at a median midpoint spacing of 90 kb,
obtained as a part of the “32k” BAC array produced by Osoegawa et al. (2001). Non-
specific hybridisation was controlled by 8 random drosophila clones that have been
shown not to hybridise to human chromosomes by fluorescence in situ hybridisation.
The microarrays were constructed by amplifying the clones by DOP-PCR
using three different primers, followed by pooling and amplification by amino-linked
PCR primer and printing on Codelink coated slides (Amersham, Uppsala, Sweden), as
previously described (Douglas et al. 2004, Fiegler et al. 2003). The tumour DNA from
uterine leiomyomas and reference DNA from pooled normal tissue samples were
labelled with Cy5- and Cy3-dCTP, respectively. Both, the leiomyoma and normal
reference samples were co-hybridised to the arrays with herring sperm DNA and COT
human DNA (Roche, Lewes, United Kingdom), followed by washing and scanning
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with a confocal scanner (Perkin Elmer, Wellesley, MA, USA). Samples with poor
hybridisation were rejected by visual inspection after which the Spot program (Jain et
al. 2002) was used for the image data quantification. After correcting for background
based on the drosophila clones, log2 ratio of the fluorescence intensities of tumour to
reference was calculated. Standard deviations of these ratios were calculated genome-
wide. Tumour-normal ratios of greater than 3 were taken to indicate gain and ratios of
less than -3 were scored as loss.
4.3 Expression microarray analysis (II, III)
Global gene expression patterns in uterine fibroids and corresponding normal
myometrium was measured by oligonucleotide microarray chips, a method proven
extremely powerful in many recent studies on various tumours (Golub et al. 1999,
Singh et al. 2002). The technology is based on a combination of solid-phase
chemistry, photolabile protecting groups and photolithography, which facilitates the
parallel synthesis of various chemical compounds (Fodor et al. 1991). This approach
makes it possible to produce high density arrays of various biological compounds in
situ based on sequence information alone (Fodor et al. 1993). The expression of tens
of thousands of genes can therefore be measured in a single experiment (Lockhart et
al. 1996, Wodicka et al. 1997).
4.3.1 Experimental procedures
For the expression microarray experiments, double-stranded cDNA was produced
from 8 micrograms of total RNA by using the SuperScript™ Double-Stranded cDNA
Synthesis  Kit  (Invitrogen,  Life  Technologies,  Carlsbad,  CA).  The  cDNA  were
purified using phenol-chloroform-isoamyl alchohol solution (Amresco, Solon, Ohio)
and Phase Lock Gel™ Heavy 1.5 ml tubes (Eppendorf AG, Hamburg, Germany),
followed by ethanol precipitation. For the production of biotin labelled cRNA, in vitro
transcription was performed by RNA Transcript Labeling Kit (Enzo Diagnostics Inc,
Farmingdale,  NY).  The  labelled  cRNA  was  then  purified  with  RNeasy®  mini
columns (Qiagen Ltd) and fragmented by metal ion catalysed cleavage at 94°C for 35
minutes in the presence of 40 mM Tris-acetate, pH 8.1, 100 mM potassium acetate,
and 30 mM magnesium acetate. Fifteen micrograms of fragmented cRNA with 0.1
mg/mL herring sperm DNA in MES buffer were hybridised on GeneChip® HG-
U133A oligonucleotide chips (Affymetrix Inc, Santa Clara, CA) at 45°C for 16 hours.
43
Subsequently, the chips were washed and stained with streptavidin-phycoerythrin
using Fluidics Station 450 (Affymetrix) and scanned using GeneChip® System
GA2500 Scanner (Affymetrix). All procedures were carried out as outlined in the
Affymetrix technical manual (Affymetrix Inc. 2004).
4.3.2 Expression data analysis
Quantitative information was derived from scanned images using MAS 5.0 software
(Affymetrix). Subsequently, the dChip 1.3 PM/MM difference model was used to
check for single, probe and array outliers, in addition to the preliminary hierarchical
clustering (Li and Wong 2001). The expression values of all genes called marginal or
present at least in 50% of the samples were selected and the data were log2
transformed and arrays were centred to the median.
For unsupervised clustering (Eisen et al. 1998), gene vectors with small
standard deviation were filtered out, typically resulting in a list of about 1000 genes
that were the most differentially expressed across the samples. Subsequently, the
arrays were organised with self organising maps, and hierarchically clustered using
Pearson correlation coefficient as the similarity metric. The cluster tree images were
created with TreeView 1.60 software (Eisen et al. 1998). Another unsupervised
classification method, principal component analysis (PCA), was also performed to
evaluate the global differences between different groups of fibroids. This was done by
utilising the TIGR MeV software (Saeed et al. 2003) and PCA method as described
(Raychaudhuri et al. 2000).
Differentially expressed genes were detected using Significance Analysis of
Microarrays (SAM) software (Tusher et al. 2001). In all SAM analyses, missing
values were imputed with K-Nearest Neighbors Imputer (10 neighbours) and a two-
class test for unpaired data was used with 5000 permutations. In addition to only
looking at individual deregulated genes, a functional group enrichment analysis
(FGEA) was performed to analyse the expression data in biologically meaningful
subgroups. For FGEA, we utilised GoMiner (Zeeberg et al. 2003) software firstly, to
find Gene Ontology (GO) (Ashburner et al. 2000) annotations for all the genes in the
microarray analysis and, secondly, to perform a two-sided Fisher’s exact test to
calculate p-values for the enrichment of each GO category in the list of differentially
expressed genes.
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In order to find out whether the expression levels of a small set of genes could
be used to classify fibroids as being either FH-mutant or FH wild-type, a molecular
classifier was developed with the method described by Golub et al. (1999). Firstly, the
Finnish set of samples was used in a leave-one-out cross-validation procedure1 for
testing the performance of predictors consisting of 1 to 10 different genes. The results
from  this  test  guided  the  selection  of  the  number  of  genes  chosen  for  the  final
predictor which was further validated on the independent set of UK fibroids. The class
assigned for tested samples was determined by 3 of its nearest neighbours using the
Cosine distance metric. The molecular predictor analysis was performed utilising
Gene Cluster software (Reich et al. 2004).
4.4  Quantitative real-time RT-PCR (II, III)
To  confirm  some  of  the  findings  discovered  by  expression  microarray  analyses,  we
performed additional experiments by quantitative real-time reverse transcriptase (RT)
PCR. Firstly, complementary DNA (cDNA) is produced from total RNA extracted
from the  samples.  Then,  a  PCR is  performed during  which  the  accumulation  of  the
PCR product is assessed in real time by detecting the fluorescence signal produced by
the product specific probe. As Taq DNA polymerase has 5'‡3' exonuclease activity,
it cleaves the probe during the PCR, if the probe hybridises with the target sequence
(Holland et al. 1991). The probe contains a reporter fluorescence dye, which is
quenched by another dye at the other end of the probe. This cleavage separates the
reporter dye from the quencher and therefore increases the reporter dye fluorescence
signal (Lee et al. 1993). The progress of the PCR can be monitored in real time as the
accumulating intensity of the reporter dye (Mullah et al. 1998).
We measured the relative expression of DAPK1, RARRES3, RINT-1, TKT,
LDHA, CDKN1A and AATF in fibroid and normal myometrium samples. TATA-box
binding protein (TBP) and β-actin (ACTB) were utilised as endogenous control genes,
as their expression did not vary significantly as measured by expression microarray
analysis. Firstly, cDNA were synthesised from total RNA utilising M-MLV reverse
1 The leave-one-out cross-validation goes briefly as follows (Golub et al. 1999): one sample is withheld
and the remaining samples are sorted according to the correlation with the phenotype; the genes with
the best positive or negative correlation are chosen for a predictor, which is then utilised for
determining the phenotype of the withheld sample. The procedure is repeated until all samples in the
initial dataset have been tested. The accuracy of the predictor is calculated as the proportion of
erroneous predictions. The final predictor is built based on all samples in the initial data set. This
predictor can be tested in an independent set of samples.
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transcriptase (Promega, Madison, WI) and 300 ng of random hexamer primers in the
manufacturer’s buffer containing 1 mmol/l of dNTP, and 40 U of RNase inhibitor
(Promega). The reverse-transcriptase reaction was as follows: 42°C for 50 min,
followed by 95°C for 10 min and 4°C for 5 min. Subsequently, the cDNA was
amplified  by  PCR,  and  the  accumulation  of  the  product  was  detected  in  real  time
utilising an ABI PRISM SDS5700 sequencing detector system (Applied Biosystems)
and TaqMan® Gene Expression Assays (Applied Biosystems). The RT-PCR
reactions were done in triplicate. The relative expression of each gene was calculated
by the equation 2-ddCt, where Ct is the mean threshold cycle of the PCR reaction at
which the accumulation of the PCR product is exponential, dCt is the difference
between  the  threshold  cycle  of  the  target  and  control  genes,  ddCt  is  the  normalised
dCt  value  derived  from subtracting  the  highest  dCt  from all  other  dCt  values  of  the
respective gene in each experiment. The statistical significance was tested by a two-
sided heteroscedastic t-test in the cases where the distribution of the data was close to
normal;  The  Mann-Whitney  U  test  was  performed  when  the  data  distribution  was
skewed.
4.5  Western blot analysis (III)
For measuring FH protein expression in uterine fibroids, we used a method called
Western blotting that was first described in 1981 by Burnette (1981). It is based on
polyacryl amide gel electrophoresis that separates the denatured proteins according to
their size, the blotting of the protein out of the gel and onto a nitrocellulose or
polyvinylidene fluoride (PFVD) membrane, and subsequent detection by protein
specific primary antibody and primary antibody specific secondary antibody.
Total protein was extracted from fresh frozen uterine fibroid specimens using
the T-PERTM Tissue Protein Extraction Reagent (Pierce, Rockford, IL) protocol and
the protein concentration was determined by BCA Protein Assay Reagent Kit (Pierce,
Rockford, IL). After denaturation, 5 µg of protein was separated on a 10%
polyacrylamide gel (Bio-Rad Laboratories, Hercules, CA) and blotted onto a PVDF
membrane (Millipore, Bedford, MA). The membranes were probed with purified
polyclonal rabbit anti-porcine FH antibody (Nordic Immunological Laboratories,
Tilburg, The Netherlands) at a 1:500 dilution. After stripping of the FH antibody, the
same membrane was probed with monoclonal mouse -tubulin antibody at a 1:10 000
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dilution (Sigma-Aldrich, St. Louis, MO) to obtain a protein loading control. Both FH
and -tubulin were detected by the ECL plus Western Blotting Detection System
(Amersham Biosciences UK Ltd, Buckinghamshire, England).
5 TEST MATERIALS
All patient materials were collected either anonymously or with the informed consent
by the patient, and the collection was approved by the local ethics committee.
5.1  Renal cell carcinomas (I)
The Finnish Cancer Registry – Institute for Statistical and Epidemiological Cancer
Research was established in 1953, and since then it has kept a record of all cancer
cases in Finland by receiving information from hospitals, practicing physicians and
pathological and haematological laboratories. Also, death certificates in which cancer
is mentioned are transferred into the registry each year (Finnish Cancer Registry –
Institute for Statistical and Epidemiological Cancer Research 2005). As reporting to
the registry is mandatory by law, and as the mortality follow-up is extremely efficient
in Finland due to the use of personal identification numbers since 1967, the coverage
of the national cancer registry is almost complete (Teppo et al. 1994). The data are
also  of  high  quality  as  less  than  1% of  the  cases  have  death  certificates  as  the  only
source of clinical information (Dickman et al. 1999), and as the histological
confirmation of cancer is received in more than 90% of cases (Finnish Cancer
Registry – Institute for Statistical and Epidemiological Cancer Research 2005). We
searched the registry for early-onset renal tumours of all histological types diagnosed
from ages 15 to 34, after which the pedigrees were extended and documented utilising
data from the Finnish population registry and patient records. Younger patients were
left out due to the high proportion of Wilms tumours in that age group (Haber 2002).
A set of 60 sporadic RCCs that comprised 30 clear-cell, 3 papillary, 2 granular cell, 1
mixed papillary/clear-cell, 1 mixed clear-cell/solid histology, 9 oncocytic papillary,
and 14 oncocytoma cases diagnosed at any age were collected at Helsinki University
Central Hospital and at Jyväskylä Central Hospital.
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5.2  Uterine leiomyomas (II, III, IV)
A set of 166 sporadic uterine leiomyomas were collected from 51 patients undergoing
a hysterectomy at Helsinki University Central Hospital. The tumour and
corresponding normal myometrium samples were snap-frozen in liquid nitrogen and
subjected for further analysis anonymously. In addition, 6 uterine leiomyomas and
corresponding myometrium were obtained from a patient carrying a germline FH
mutation 541delAG (Tomlinson et al. 2002). The DNA was extracted by the Fast
DNA® Kit (Bio 101, Carlsbad, CA, USA), which utilises ceramic spheres and a rapid
shaking and twisting motion at very high speeds to homogenise the tissue sample
rapidly, or by a standard non-enzymatic method (Lahiri and Nurnberger 1991). Of the
samples subjected to expression microarray studies, frozen sections were
haematoxylin-eosin-stained and the diagnosis was confirmed. The mitotic rate was
assessed and cellularity was semi-quantitatively graded from 1 to 3, with 1 defined as
high,  2  as  medium  and  3  as  low  stroma/nuclei  ratio.  RNA  was  extracted  using  the
Trizol® reagent (Gibco BRL, Life Technologies Inc., Gaithersburg, MD) and an RNA
clean-up with RNeasy® mini columns (Qiagen Ltd, West Sussex, UK) was performed.
For the expression microarray experiment, RNA integrity was verified by an Agilent
2100 Bioanalyzer RNA 6000 Nano Chip (Agilent Tecnologies, Waldbronn, Germany)
analysis.  The  samples  with  poor  RNA  quality  were  subjected  to  a  second  round  of
RNA extraction. A separate sample set for expression microarray studies was
obtained in The United Kingdom: 3 samples of normal myometrium; 2 sporadic, FH
wild-type fibroids; and 5 FH-mutant  fibroids  from  a  HLRCC  patient  carrying  a
germline FH mutation K187R (Tomlinson et al. 2002). Also, DNA from a UK set of
174 sporadic uterine fibroids was utilised for LOH and aCGH analyses.
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6 RESULTS
6.1  Renal cell canrcinomas (I)
The computerised search of the Finnish Cancer Registry revealed 244 unrelated
patients with RCC diagnosed at age 15 to 34. Cases with diagnosed VHL and Wilms
tumour were excluded, in addition to cases diagnosed before the year 1985, as older
paraffin embedded tissue blocks would have been hard to obtain. This left 84 index
cases, for which the pedigrees were expanded to include first degree relatives and
their cancer status derived from the cancer registry records; 19 interesting families
suggesting possible inherited cancer were found, including Family A (Figure 3). For
the remaining 18 families, the investigations are still ongoing. The index case had
received the diagnosis of RCC at age 28, when the tumour had already metastasised.
The kidney was resected in a palliative operation. Histologically, the tumour was
defined as a clear-cell carcinoma that showed a mixture of clear cells and cells with
granular-eosinophilic cytoplasm. In the cancer registry records, the proband’s mother
was defined as having suffered from a malignant tumour of the heart, which in further
examination of the patient records turned out to be a malignant paraganglioma
growing from the septum to the right ventricle. She received the diagnosis at the age
of 55, and as the tumour was considered inoperable, it subsequently led to the demise
of the patient. Two of the proband’s maternal uncles had also suffered from cancer;
one had a small-cell lung carcinoma diagnosed at age 55, and the other pancreatic
carcinoma diagnosed at age 71.
To test the hypothesis that early-onset renal cell cancer is caused by the
syndrome HLRCC, DNA from these samples was derived from archived paraffin
embedded tissue blocks and subjected to FH mutation analysis. No changes were
observed, however. As mutations in the genes encoding subunits of SDH had been
detected in familial paragangliomas, an alternative hypothesis of SDH involvement in
the tumour predisposition in Family A was tested by directly sequencing all 4 SDH
genes, SDHA, SDHB, SDHC, and SDHD. This revealed a truncating mutation R27X
in the SDHB gene. Both the proband and his mother carried the mutant allele, and the
wild-type allele was lost in the proband’s RCC and in the mother’s cardiac PGL. The
maternal uncle with lung cancer was also a carrier of the mutant allele, but no loss of
the wild-type was observed. From the uncle with the pancreatic cancer, no DNA was
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available  for  analysis.  In  the  further  screen  of  all  four  SDH  genes  in  the  set  of  60















Figure 3. Family A ascertained through the search at the Finnish Cancer Registry database.
6.2 Uterine leiomyomas (II, III, IV)
6.2.1 Leiomyoma histology (II, III)
To confirm and scrutiny the diagnosis, HE stained frozen sections from the Finnish
samples subjected to microarray experiments were subjected to pathologist’s review.
All fibroids were histologically classified as typical leiomyomas. All had a mitotic
rate of less than 1 per 10 high-power fields, and the semi-quantitative assessment of
cellularity  classified  them into  3  groups  as  follows:  22% in  class  1,  73% in  class  2,
and 5% in class 3. A trend for greater cellularity in FH-mutant fibroids was observed,
as none of them belonged to class 1, and the only tumour in class 3 was FH-mutant
(p=0.101, Fishers’s exact test).
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6.2.2 Microsatellite analysis on 1q and FH mutation analysis (III)2
The microsatellite analysis was performed on the set of 166 fibroid and 51
corresponding normal myometrium samples. At the loci flanking the FH locus, 46
individuals (153 tumours) were informative at least with 1 of the 2 markers. Allelic
imbalance  was  observed  in  5  samples.  Of  the  6  Finnish  HLRCC fibroids,  4  showed
LOH on chromosome 1q indicating loss of the wild-type FH: The sporadic fibroids
harbouring  AI  on  1q  were  subjected  to  mutation  analysis  of  the  FH  gene;  Two
mutations were detected, a missense mutation c.586G>A (p.A196T) in sample 32m1,
and a splice-site mutation IVS4 + 3A>G in sample 4m3. The corresponding normal
myometrium and all other tumour samples from these patients were also subjected to
FH mutation analysis, but no changes were detected. No second point mutation was
detected either in the HLRCC fibroids.
6.2.3 7q LOH mapping (II)
The 166 sample set was also subjected to LOH mapping on chromosome 7q. All
tumours were informative with the majority of 25 markers covering about 20 Mb on
chromosome 7q21-q31, and 11 (8 different patients) showed allelic imbalance with at
least 2 markers. Three individuals (9, 14, and 38) had 2 different tumours that showed
LOH  on  7q,  in  2  cases  (9  and  38)  the  lost  alleles  were  the  same,  but  in  case  14
different chromosomes were lost in 2 different tumours of the same patient. In most of
the cases, the regions of AI were consistent, and there were no regions where
heterozygosity was retained in the middle of AI. Three tumours did not meet the
criteria  for  LOH  with  all  markers  within  the  region  of  AI,  but  true  retention  of
heterozygosity and thus the possibility of a homozygous deletion was ruled out by a
clear trend towards LOH seen in the allele intensity curves. The microsatellite
analysis defined a common region of AI flanked by markers 7qAC005070 on 7q22.3
and 7qAC007567 on 7q31.1 being compatible with a deletion of 3.2 Mb. This region
harbours at least 22 different transcripts, 20 of which are represented on the HG-
U133A chip by 31 different probe sets.
2 The  1q  LOH  and FH mutation analysis of the set of 166 sporadic fibroids has been published by
Lehtonen et al. (Lehtonen et al. 2004), and is not part of this thesis work. However, since the methods
and samples are the same, and as the identification of these sporadic FH mutant fibroids was crucial for
the expression microarray study of this thesis, the information is presented here.
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6.2.4 Microarray comparative genomic hybridisation (aCGH) (II, IV)
To further analyse the nature of the AI observed in the fibroids, aCGH experiments
were performed. The first analysis was performed with a 1 Mb resolution aCGH chip
of the whole genome. Ten out of the 11 fibroids with 7q LOH were successfully
hybridised, and 8 of them showed deletion in the region predicted by LOH; two
samples did not show any changes in the region of AI. On the other hand, one of them
(51m1) demonstrated whole chromosome gains of chromosomes 8, 9, 12, 14, and 19.
No homozygous deletions were observed. The same approach was also applied to the
HLRCC fibroids from the UK; all showed LOH on chromosome 1q.
 To further scrutiny the deletions on 7q, a tiling path aCGH focusing on
chromosome 7q was produced and more fibroid samples from the UK were added to
the experiment. Altogether 42 uterine leiomyoma samples were tested against a
common  female  normal  DNA;  20  of  them  showed  deletion.  The  deletions  were
clustered around two different regions. The first was delimited proximally by clone
RP11-437M1 in sample 38M1, and distally by clone RP11-443I10 in sample 34M1,
with a length of 2.79Mbp, consistent with the microsatellite analysis. The second
deletion was observed in 5 samples and was located between clones RP11-795E24 in
sample 14M4, and RP11-786A19 in sample 29M2. No homozygous deletions were
observed with the high-resolution array CGH.
6.2.5 Gene expression analysis (II, III)
A total of 33 samples from 12 patients were successfully hybridised on expression
microarray chips (III). There were 11 samples of normal myometrium (N), and the 22
tumour samples consisted of 3 different subgroups: 9 fibroids with AI on chromosome
7q (7QD), 6 fibroids with no detected AI on 1q or 7q (N7Q), and 7 samples with
mutations of the FH gene. A preliminary unsupervised hierarchical cluster tree
(Figure 4) with all 33 samples was constructed using the 466 most differentially
expressed genes within the samples set. The procedure divided the samples into 3
major branches, one mainly consisting of normal myometrium, one of fibroids
carrying FH mutations, and one of FH wild-type samples, some of which carried 7q
deletions. Also, technical issues did not seem to be a major cause of differential gene
expression as the samples did not cluster according to the person who had prepared
the samples or the day on which the samples were run (Figure 4).
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Figure 4. An unsupervised cluster tree of all samples. Date refers to the hybridisation batch; S/P to
different person performing the hybridisation; N normal; T tumour; 7q del, samples showing AI on
chromosome 7q; FH def, samples carrying FH mutations.
6.2.6 Fibroids compared to normal myometrium (II)
The first comparison of gene expression data was conducted with the FH wild-type
and normal myometrium only. This allowed us to compare our own data with already
published results on fibroid gene expression without the confusing effect of the
apparently different FH-mutant fibroids. By comparing the groups 7QD and N7Q
together to the normal myometrium samples, 133 differentially expressed probe sets
were identified with a 5% rate of estimated false discoveries. Fifty four of them were
up-regulated and 79 down-regulated in the fibroids. Of some genes, several
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independent probe sets were available providing an internal control for the
reproducibility of the expression data. For example, FN1 was represented by 4 probe
sets, the fold-changes of which ranged from 1.72 to 1.79, increasing our confidence in
the data.
Although several interesting individual genes, such as growth arrest and
DNA-damage-inducible beta (GADD45B), retinoic acid receptor responder 3
(RARRES3), homeo box A5 (HOXA5), B-cell CLL/lymphoma 6 (BCL6), death-
associated protein kinase 1 (DAPK1), cyclin D1 (CCND1), phosphodiesterase 8B
(PDE8B), transcription factor AP-2 gamma (TFAP2C), and protein kinase C beta 1
(PRKCB1), were observed to be deregulated in fibroids, the power of genome wide
expression analysis lies in the simultaneous detection of changes in multiple
functionally related genes, that is the pathways. Gene Ontology (GO) annotations
were utilised to group the genes into biologically meaningful categories. Almost 90%
(87 out of 111) of the genes differentially expressed could be put into one or more
categories and together they belonged to 515 different groups. A functional group
enrichment test  showed that 40 of the ontology terms represented by more than two
genes were enriched with genes differentially expressed (unadjusted p-value < 0.05).
However,  several  of  them  were  overlapping  or  nearly  identical,  and  thus  the  true
number of differentially expressed functional groups was substantially lower. For
example, genes related to transcription, 4 of which were up-regulated (SATB2, SOX4,
TFAP2C, TRPS1) and 13 down-regulated (ATF3, BCL6, CITED2, EGR1, GATA2,
HOXA5, JUN, KLF2, KLF4, MSX1, NFIB, NR3C1, NR4A2) in fibroids, belonged to
multiple different groups (Transcription Factor Activity, Transcription, Transcription
Regulator Activity, and DNA Binding). Other categories with increased
representation on the list of differentially expressed genes were such as Response to
Stress with 13 genes, 3 of which were up-regulated (DDB2, ERCC3, FN1)  and  8
down-regulated (APOL3, BCL6, C1R, C1S, GADD45B, MAP3K5, NR3C1, NR4A2,
PDLIM1, SMAD7) and Extracellular Matrix with 9 genes up-regulated (COL1A1,
COL3A1, COL4A1, COL4A2, COL5A2, COL9A2, LTBP2, MFAP2, MMP11)  and  2
down-regulated (LTBP1, TNXB) in fibroids. If a conservative Bonferroni adjustment
for multiple testing was applied, only 3 categories, all representing extracellular
proteins (Extracellular Matrix Structural Constituent, Collagen, and Extracellular),
reached a statistically significant confidence of enrichment.
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6.2.6.1 Fibroids with 7q-deletions compared to fibroids without deletions (II)
The next objective was to compare the 2 groups of FH wild-type fibroids (7QD and
N7Q) to each other in order to specify the global changes on the gene expression
profile caused by chromosomal deletions of 7q. As already indicated in the
unsupervised clustering of the fibroids, the changes between 7QD and N7Q fibroids
were not very significant. In trying to identify the most differentially expressed genes,
this was reflected by the large number of estimated false discoveries; even with the
most  stringent  conditions,  FDR  was  estimated  to  be  >50%.  A  two-sided
heteroscedastic t-test was utilised to identify the most likely genes affected by the 7q
loss, and the 107 probe sets with a p-value of less than 0.01 were further analysed for
enrichment in any particular GO category. Altogether, 22 categories with 2 or more
genes had an unadjusted p-value less than 0.05, and the categories most clearly
enriched were Nuclear Membrane, ER to Golgi Transport, Endomembrane System,
and Nucleic Acid Binding, although none survived the Bonferroni correction for
multiple testing.
Although the global expression pattern did not significantly differ between
7QD and N7Q, the possibility remained that the expression data could give some
clues as to which gene within the commonly deleted region could function as a
tumour  suppressor.  Therefore,  the  expression  of  the  probe  sets  located  between  the
clones AC005070 and AC007567 were evaluated in more detail. The 31 probes
represented 20 of the 22 different transcripts in the region, and thus expression data
was not obtained from 2. In addition, 6 probe sets were called absent in all 25
samples, 2 probe sets were present only in 1 sample and 1 probe set only in 2 samples.
Also, one of the probe sets representing PP35 was detected in 5 normal samples but
only in 3 tumours. This left 13 transcripts out of 22 that were consistently expressed at
detectable levels. Most of these genes showed marginal down-regulation in 7QD
fibroids,  although no  single  gene  stood  out  as  a  striking  candidate  (II).  Only  two of
them had an unadjusted p-value smaller than 0.05: component of oligomeric golgi
complex 5 (COG5, p = 0.02) and Rad50-interacting protein 1 (RINT-1, p = 0.04).
COG5,  however,  had  also  another  probe  set  that  did  not  show  as  clear  a  down-
regulation.
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6.2.6.2 Fumarate hydratase-deficient fibroids (III)
To test the hypothesis that FH-mutant fibroids form a distinct group among uterine
fibroids, the expression profile of FH-mutant fibroids was compared to that of groups
7QD and N7Q in the Finnish set of samples. Firstly, a hierarchical clustering analysis
of only the fibroids was performed. This separated the fibroids into two major
branches, one of which comprised both sporadic FH-mutants, all but one HLRCC
fibroid, and both fibroids from patient 44 (III). The samples were also separated
according  to  their  FH-status  in  the  principal  component  analysis  plot  (III).  When  a
FDR of 5% was allowed, 360 probe sets showed differential expression between FH-
mutant and wild-type fibroids. They corresponded to 297 genes, 41 of which were
represented by more than 1 probe set, showing consistent changes in gene expression.
A GO annotation could be assigned for 214 of these genes, and they belonged to 1519
different categories. In the functional group enrichment test, 50 of them showed
significance at the level of 1%. Genes belonging to Hexose Metabolism category were
the most significantly enriched group within the differentially expressed genes (p =
1.7 E-09) and, for example, all 10 differentially expressed genes involved in
Glycolysis (p = 1.1 E-08) had higher expression in FH-mutants.  In  fact,  of  the  50
categories, 14 were directly involved in carbohydrate metabolism, and all but a few of
the genes, such as FH, had higher expression in FH-mutants. Additional categories
with higher expression in FH-mutants included Iron Ion Homeostasis, Oxidoreductase
Activity, Membrane Lipid Catabolism, Integral to Endoplasmic Reticulum
Membrane, and Electron Transporter Activity. Genes with lower expression in FH-
mutants, on the other hand, tended to belong to functional categories such as
Extracellular Matrix, Cell Motility, Muscle Contraction, Organogenesis, Muscle
Development, Cell Adhesion, and Plasma Membrane. When a conservative
Bonferroni correction was applied, only 10 categories, all representing genes involved
in carbohydrate metabolism, showed significant enrichment on the list of
differentially expressed genes. In addition, known HIF target genes (Semenza 2003),
not a GO category, showed significant enrichment within the differentially expressed
genes (p = 2.2 E-08); of the 45 genes tested, 13 had higher expression in FH-mutant
fibroids.
The expression profile of FH-mutant fibroids was also compared to the normal
myometrium. The genes involved in glycolysis were again highly significantly over-
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represented among on the list of differentially expressed genes (p = 1.3E-07), and all
categories that survived the Bonferroni correction were related to carbohydrate
metabolism. Also, many other genes showing higher expression in FH-mutant
fibroids when compared to FH wild-type fibroids, such as NQO1, AKR1C1, TKT,
CDKN1A, ME1, PRDX1, PRDX4, PRDX6 and LDHA, showed higher expression
when compared to normal myometrium.
The expression data from the UK fibroids facilitated the validation of our
findings in an independent set of samples. To test the overall similarity of the Finnish
and UK samples, an unsupervised clustering was performed; the UK HLRCC fibroids
clustered together with the Finnish FH-mutants, and the UK sporadic fibroids
clustered with the Finnish FH wildtypes (Figure 5). This gave confidence that the two
sets of samples were, at least to some extent, comparable with each other. An
unadjusted t-test was performed to find the genes most significantly differentially
expressed between the UK normal myometrium and HLRCC samples. This confirmed
the up-regulation of several genes involved in glycolysis, such as LDHA (FC 2.3, p =
0.04), ENO1 (FC 2.5, p = 0.0006), PKM2 (FC 2.0, p = 0.026), PFKP (FC 3.0, p =
0.01), and PGAM1 (FC 1.6, p = 0.01). The up-regulation of TKT (FC 2.5, p = 4.8E-7),
NQO1 (FC 2.5, p = 0.005), and CDKN1A (FC 4.3, p = 0.016) was also confirmed.
Indeed, most genes behaved in a similar way in the UK sample set, although statistical
significance was not seen in all cases. There were, however, genes the deregulation of
which could not be confirmed; CDKN1C, for example, was the sixth most
significantly down-regulated gene in the Finnish sample set (FC 0.35, q = 0.0026),3
but in the UK set the significant down-regulation was not observed (FC 0.9, p = 0.57).
A molecular predictor based on gene expression data was also built to test
whether a small number of genes (<10) could be used to predict the FH status of
fibroids. In the leave-one-out cross-validation performed on the Finnish set of
samples, a predictor consisting of LDHA, NQO1, LAMA2, BNIP3, MYO15B,
CDKN1C, and COL6A2 gave the best results, and thus it was subsequently tested on
the independent set of 7 UK fibroids. The 7-gene classifier correctly predicted the FH
mutation status of all UK fibroids.
3 The q-value is a modified p-value based on the estimated false discovery rate described by Tusher et
al. (2001).
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Figure 5. An unsupervised cluster tree of the Finnish and UK samples. UK FH-mutants (HLRCC1-4,
capsule) clustered together with Finnish FH-mutants and UK FH wildtypes (Sporadic1m, 2m) clustered
together with Finnsih FH wildtypes.
6.2.7 RT-PCR (II, III)
In order to validate some of the expression data with an independent method,
quantitative real-time RT-PCR was performed on some of the genes. The down-
regulation of DAPK1 and RARRES3 in FH wild-type fibroids compared to normal
myometrium was confirmed as both showed significant down-regulation with p-
values of 0.019 and 0.038, respectively. As marginally significant down-regulation of
RINT-1, a gene within the commonly deleted 7q-region, was observed between 7QD
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and N7Q fibroids, further expression analysis was performed, but no significant
deregulation was detected (p = 0.75). A similar approach was applied to evaluate
some of the genes defining the FH-mutant expression profile, the higher expression of
TKT (p = 0.006), LDHA (p = 0.023), CDKN1A (p = 0.043) and AATF (p = 0.004) in
FH-mutant fibroids compared to FH wildtypes was confirmed.
6.2.8 Western blotting (III)
As 10 out of 12 FH-mutant fibroids included in the expression analyses showed
robust genetic evidence for loss of FH (all UK HLRCC fibroids showed 1q deletion,
the Finnish sporadic FH-mutants and 3 out of 5 HLRCC tumours showed 1q LOH), in
only 2 cases the loss of FH was not genetically confirmed. Also, although FH
mutation negative, both fibroids from patient 44 clustered together with FH-mutant
fibroids in the expression microarray analsis (III). Therefore, Western blot analysis
was performed to evaluate the FH protein level in 7 samples, normal myometrium
B7n and 44n, and fibroids B7m1 (no 1q LOH), B7m2 (showed 1q LOH), B7m3 (no
1q LOH), 44m2 and 44m3. Of the HLRCC fibroids, B7m1 had clearly the highest FH
level, but no reduced expression of FH was observed in 44m2 or 44m3 (III).
6.2.9 7q gene screening (IV)
For the 7q candidate gene screening, the minimal deleted region was defined
proximally by the clone RP11-437M1; the distal delimiting marker was D7S496 as
reported by Mao et al. (1999). Within this region, 10 manually annotated known
protein coding genes (Ashurst, et al., 2005) were identified. In addition, DLD was
sequenced as it was deleted in most samples with del(7q) and as it encodes a subunit
of -ketoglutarate dehydrogenase, an enzyme of the Krebs cycle. The genes were
amplified in 134 PCR fragments, thus altogether 1474 PCR fragments in 11 samples
were analysed; the success rate was ~93.8%. Altogether, 13 sequence alterations were
observed in 8 genes (IV). Most of them (8) were known SNPs and they were observed
in frequencies compatible with known allele frequencies available in the Ensembl
data base. Of the novel SNPs, 4 were synonymous; one non-synonymous change was
observed in RINT-1 (c.349A>T, p.S69C). It was present as a homozygous change in 2
out of 8 patients (3 of 11 fibroids). A set of 93 healthy controls were also screened for
this novel SNP, the frequency of the novel allele was 16%.
59
7 DISCUSSION
The work described herein has tried to answer some of the questions that arose from
the identification of the molecular background of HLRCC. The research has followed
two main lines, one of which is based on role of FH in renal cell cancer (I). The
second line of research has focused on the molecular biology of uterine fibroids (II,
III, and IV).
7.1  Renal cell carcinomas
As early-onset RCC is a component of the HLRCC, it was hypothesised that there
should be FH-mutation  carriers  among  patients  who  have  suffered  from  RCC  at  a
young age. Thus, a computerised search in the Finnish cancer registry database was
conducted.  The  RCC  cases  in  the  Finnish  HLRCC  families  are  of  papillary  type  II
histology, but as there had not been any previous studies showing that only this type
of RCC is associated with HLRCC, all histological subtypes were included in the
analysis. The search resulted in a list of 19 interesting families. Although the original
hypothesis was that some of these patients should carry mutations in FH, the medical
history of Family A (Figure 3), especially the cardiac paraganglioma in the index
case’s mother, suggested that SDH could be involved instead. Indeed, both the index
case and his mother carried germline R27X mutation in the SDHB gene. Both tumours
showed loss of the wild-type allele in the tumour sample, suggesting that SDHB acted
as a tumour suppressor, an observation compatible with earlier studies on SDHB-
related tumours.
This Finnish case of clear-cell RCC in the SDHB-paraganglioma syndrome
was  the  first  indication  that  malignant  renal  tumour  might  be  a  component  of  the
syndrome. Interestingly, at the same time, studies in a population-based registry of the
Freiburg-Warsaw-Columbus Phaeochromocytoma Study Group, which registers all
clinical phaeochromocytoma cases diagnosed in Germany and central Poland, and at
the time had 352 unrelated registrants, identified another family with an SDHB
germline mutation c.847-50delTCTC in which 2 siblings had suffered from early-
onset RCC with solid histology at ages 24 and 26, respectively (Family B, Figure 6).
Both RCCs showed loss of the wild-type allele at the mutation locus suggesting that
the function of SDHB had been abolished, and both siblings suffered from
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paraganglioma as well. Together these studies strongly suggested that RCC did not
occur in these patients by chance but truly belonged to SDHB-associated tumour
predisposition. The mutation screening effort was extended to cover all 4 SHB-genes
in a mixed set of 60 Finnish sporadic RCCs, but no mutations were detected. In
addition, a separate set of 35 clear-cell RCCs diagnosed before the age of 50 were
screened for all 4 genes in America with negative results.







Figure 6. Family B ascertained from the Polish-German registry of phaeochromocytomas.
RCC provides a link between FH- and SDH-associated neoplasia. Although
the  histological  types  of  these  tumours  are  different,  mostly  papillary  type  II  in
HLRCC and clear-cell or solid histology in SDHB-associated tumours, all these
tumours arise from the proximal tubule cells in the kidney. Both SDH- and FH-
deficient cells have been shown to over-express HIF and its target genes (Isaacs et al.
2005, Selak et al. 2005). Also, HIF-stabilisation is important in VHL-associated clear-
cell RCC development (Kim and Kaelin 2004), Tsc2-deficient RCCs over-express
HIF2 and its target genes (Liu et al. 2003), and hepatocyte growth factor (HGF),
which is the ligand for the MET receptor tyrosine kinase, triggers a signalling cascade
that activates HIF1 (Tacchini et al. 2001). Thus it seems that the unifying theme
behind most familial RCCs is HIF-signalling.
If this finding is further confirmed, it will establish a new form of hereditary
RCC. Therefore, it has immediate clinical implications for the medical surveillance of
both  patients  with  early-onset  RCC  as  well  as  familial  paraganglioma  or
phaeochromocytoma. It is notable that patient II-1 in Family B (Figure 6) received his
61
diagnosis of RCC before the paraganglioma was diagnosed. Also, as a significant
amount of apparently sporadic paraganglioma/phaeochromocytoma has undetected
germline mutations in SDH-genes, the risk of RCC should be kept in mind also in the
follow-up of these patients.
Thus  far,  only  3  cases  of  RCC  have  been  detected  in  families  with  SDH-
related paraganglioma. In the German-Polish registry, 2 cases of RCC were identified
among 31 SDHB mutation carriers, but more cases could still develop as 40% of these
individuals are younger than age 20. Therefore, the risk of RCC within SDHB
mutation carriers could be estimated to be 5-10%. However, as both cases were
diagnosed in the same family, it seems that all individulas do not have the same risk
of  RCC.  This  resembles  HLRCC,  in  which  there  are  clear  differences  in  the  risk  of
malignant phenotype between families (Kiuru and Launonen 2004). The possibility of
a genetic modifier for the risk of RCC in HLRCC has been vigorously studied,
although no candidates have been identified yet. Whether such a modifier exists, and
whether  the  same modifier  could  affect  the  risk  of  RCC among HPGL patients  also
remains to be seen.
7.2 Uterine leiomyomas
The part of the study that was aimed at uterine fibroids was conducted to test 3
different hypothesis related to fibroid biology (see Hypotheses on page 38). Based on
previous studies, recurring chromosomal rearrangement had been commonly observed
on chromosome 7q. In this study we further scrutinised the commonly deleted 7q
region and analysed whether the presence of 7q-deletions significantly affected
fibroid gene expression profile. In addition, the known genes within the commonly
deleted region were screened for mutations. Also, fibroids carrying mutations in the
FH gene were compared to FH wild-type fibroids by gene expression profiling.
7.2.1 7q fibroids
The microsatellite analysis of chromosome 7q revealed a common 3.2 Mb region of
allelic imbalance of within 7q22.3-q31.1, flanked by clones AC005070 and
AC007567. This region of AI was observed in 11 out of 166 fibroids. No retention of
heterozygosity was observed within the regions of AI, although some of the markers
did not meet the criteria for AI in all samples. Also, in different samples, the allele
intensity peak of the lost  allele varied to some extent.  Although it  could only result
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from the varying amounts of normal contaminating cells in the sample, the possibility
that some tumours would be mosaics with regard to 7q AI could not be ruled out
(Xing et al. 1997). When this result was combined to that of Mao et al. (1999), the
smallest common region of AI was only 2.3 Mb.
Allelic imbalance, or LOH, is detected by assessing the relative abundance of
maternal  and  paternal  alleles  at  the  site  of  a  polymorphism.  If  a  tumour  sample  is
completely pure and no normal cells are present, heterozygosity is truly lost when all
copies  of  a  particular  allele  are  derived  from  one  of  the  parents.  This,  however,  is
seldom the case, as normal and tumour cells grow and interact together in vivo,
therefore  resulting  in  normal  tissue  contamination.  LOH  can  occur  either  by  a  true
loss of a particular allele, or by a mechanism that only changes the relative amount of
alleles without any effect on gene dosage. The latter can be achieved at least by three
different mechanisms (Gaasenbeek et al. 2006). Firstly, one chromosome homologue
can be lost while the remaining homologue is duplicated (or one homologue is
duplicated and then the second homologue is lost). This would result in whole
chromosome loss. Secondly, LOH from a telomere and extending to a part or whole
of the chromosome arm can result from break-induced replication in a process
referred to as mitotic recombination. Thirdly, interstitial LOH can be observed after a
process called gene conversion that occurs through a mechanism probably similar to
mitotic recombination. Therefore, solely by analysing LOH it is not possible to detect
chromosomal deletions, only AI.
An additional source of information that can help in understanding
chromosomal rearrangements is comparative genomic hybridisation. While this
method measures the abundance of DNA in comparisons to normal genome dosage, it
can identify chromosomal copy number changes without the information on the
relative number of different parental alleles. Thus, these two methods, LOH analysis
and aCGH complement each other, and they have been used together successfully to
analyse chromosomal rearrangements, for example in colorectal cell lines, in which
the chromosome aberrations were found to be sometimes complex and explainable
only with more than 2 independent genetic events (Gaasenbeek et al. 2006).
The Finnish fibroid samples showing AI on 7q were further analysed with
aCGH to study the nature of AI. In addition, 35 UK samples from a set of 309
fibroids, 25 of which showed AI on 7q, were included in the aCGH analysis. This
showed  that  the  region  of  LOH  was  most  often  due  to  chromosomal  deletions,
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although some samples did not show copy number changes. No copy number changes
were observed in samples showing no AI on 7q, and no homozygous deletions were
detected. As commonly deleted chromosomal regions have been shown to harbour
tumour suppressor genes, this finding was consistent with our hypothesis H2 (Gnarra
et al. 1994). Homozygous deletions have been shown to harbour tumour suppressor
genes (Devilee et al. 2001, Li et al. 1997) and therefore such deletions could have
further narrowed our minimal deleted region. This was the first time the existence of
small homozygous deletions on chromosome 7q has been studied in uterine fibroids,
and it seems that at least they are not a common event in uterine fibroids. However,
the presence of deletions smaller than 90 kb would not have been detected with the
high resolution aCGH used, and therefore, small deletions may have escaped our
analysis.
An expression analysis in which fibroids showing 7q LOH were compared to
fibroids with no 7q LOH was performed, aiming at the detection of putative tumour
suppressor genes as down-regulated genes. At the global level, 7QD and N7Q
fibroids did not significantly differ from each other, as shown in the unsupervised
clustering of the samples. The same was reflected in the fact that no significantly
differentially expressed genes could be detected between the two groups. This
suggested that 7q-deletions do not have a significant effect on fibroid gene expression
profile, therefore contradicting hypothesis H3. Still, it might be that the deletions
target an important gene or genes which contribute to the development of these
tumours. Therefore, a more targeted analysis was performed to look at only the genes
within the commonly deleted region. Although the expression of most genes within
the minimal deleted region was detected, the analysis could not unequivocally
identify a clear candidate gene. Most genes in this region showed down-regulation in
7QD fibroids, but statistically significant down-regulation was not observed.
The known protein coding genes within the commonly deleted region were
screened for mutations, but no pathogenic changes were detected. This finding could
be due to several reasons (Devilee et al. 2001). Firstly, it could mean that the initial
hypothesis (H2) is wrong and that there is no leiomyoma suppressor within the
commonly deleted region. Also, the tumour suppressor might not be a known gene, in
which case further sequencing of the remaining putative genes within the region
could  prove  fruitful.  The  mutations  may  not  reside  within  the  coding  region  of  the
putative suppressor gene and therefore the search for the mutations should have been
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conducted within the regulatory regions of these genes. In addition, the tumour
suppressor could lie outside of the region covered by mutation analysis, or there
might be more than one leiomyoma suppressor on 7q. Evidence that the commonly
deleted 7q region breaks down into several different regions has been provided in a
recent study that detected a small 500 kb deleted region proximal to our minimal
deleted region (Sell et al. 2005).
Recent reports have shown that PBEF,  a  gene  within  the  commonly  deleted
region on 7q, functions as an insulin-like regulator of glucose homeostasis (Fukuhara
et al. 2005), as well as a factor regulating arterial smooth muscle cell maturation and
response  to  apoptosis  (van  der  Veer  et  al.  2005).  PBEF  was  shown  to  promote
vascular smooth muscle cell differentiation through an NAD+-dependent mechanism,
and when PBEF was  down-regulated  by  siRNA,  the  process  was  slowed  down.
Although these results were obtained with vascular smooth muscle cells, the PBEF
could also have a role in uterine fibroid development. PBEF showed down-regulation
in all fibroids compared to normal myometrium, but a difference between 7QD and
N7Q fibroids was not detected. It is possible, however, that 7q-deletions are only one
method of down-regulating PBEF and that the same effect could be achieved by other
mechanisms, such as promoter hypermethylation, in N7Q fibroids. This has not,
however, been studied. As the mutation analysis did not detect any point mutations in
PBEF, there is no evidence of a second hit in the PBEF gene. Thus, PBEF could be
haploinsufficient (Cook and McCaw 2000), and therefore only one hit could be
enough to promote tumorigenesis. In this case, the mutation screening should have
been targeted to the group in which no 7q-deletions were detected. The
haploinsufficiency model cannot as easily be accommodated to cover tumours in
which LOH is observed but that do not show deletion. If a gene would have a
mutation, the duplication of the mutant chromosome would lead to complete loss of
the functional gene whereas, if there were no mutation, the LOH would not have an
effect  at  all.  Therefore,  a  50%  decrease  in  the  gene  dosage  could  not  be  easily
achieved. In the initial aCGH screen, 2 out 10 fibroids showed LOH but no deletion.
One of these samples showed deletion in the tiling-path array, the other sample failed.
These results indicate that the vast majority of 7q LOH in fibroids is caused by
deletions and, thus, the haploinsufficiency model has to be kept in mind.
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7.2.2 Fumarate hydratase-deficient fibroids
In a recent study by Lehtonen et al. (2004) the involvement of FH mutations  in
sporadic uterine fibroids was examined through microsatellite analysis of
chromosome 1q and subsequent FH mutation screening. Out of 153 informative
cases, 5 showed LOH and 2 of these carried mutations in the FH gene.  None of the
other fibroids from the same patients had FH mutations,  nor  were  the  mutations
detected in the corresponding normal myometrium indicating that the mutations had
been acquired some time during the fibroid formation, followed by clonal expansion
of the mutant tumour cell population. The result indicated that FH is indeed involved
in the formation of a subset of sporadic fibroids, and that as in most cases of HLRCC
tumours, two independent hits are required for tumorigenesis. This further supported
role of FH as a tumour suppressor gene, following the Knudson’s two-hit hypothesis.
The frequency of FH alterations in sporadic fibroids has been studied by other groups
too (Barker et al. 2002, and 2006, Gross et al. 2004). Both studies by Baker et al.
resulted in negative results, but Gross et al. concluded that karyotypic alterations of
the FH locus might indeed play a role in sporadic fibroids. Taken together, the
evidence supports the role of FH in a small subset of sporadic fibroids. As no sporadic
mutations have been detected in studies performed on samples from other populations
than Finnish, it could be that there are some modifying genetic or other factors that
could favour the tumorigenesis to follow the pathway that involves loss of FH. A
similar pattern of incidence has been observed regarding uterine leiomyosarcoma, as 3
Finnish HLRCC families have cases of leiomyosarcoma, a tumour type that has not
been detected in families from other populations (Kiuru and Launonen 2004). A
recent study indeed shows that Finnish HLRCC patients seem to have an increased
risk for developing leiomyosarcoma (Lehtonen et al. 2005), although somatic
mutations in FH are rare in these tumours (Ylisaukko-Oja et al. 2006).
To test hypothesis H4, according to which FH-deficient fibroids form a
distinct subclass of fibroids, expression microarray analysis was conducted. Already
the unsupervised clustering of all samples suggested that FH-mutant fibroids, both
sporadic  and  HLRCC,  were  significantly  different  from  their FH wild-type
counterparts. The FH-mutant fibroids formed their own cluster and, furthermore,
principal component analysis separated the samples into distinct groups (III), except
for sample B7m1, which tended to cluster with FH wild-type fibroids. This raised the
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question whether this sample would actually not be FH-deficient and thus represent a
non-syndromic fibroid in a syndromic patient. Western blot analysis confirmed that in
contrast to B7m3, another fibroid that did not have a second genetic hit on FH, B7m1
expressed FH protein. Therefore, the global gene expression analysis of fibroids
suggested that FH-mutants, regardless of their origin, have a distinct expression
profile and, for this profile, two hits in FH are required. Two hits have indeed been
detected in most HLRCC tumours (Kiuru and Launonen 2004).
As already indicated by the clear differences at the global gene expression
level, a number of significantly differentially expressed genes between FH-mutants
and wildtypes were detected. A gene ontology (GO) based approach for mining
functional groups in the set of differentially expressed genes found that most
significantly enriched gene categories were related to carbohydrate metabolism. Most
of these genes were up-regulated in FH-mutant  fibroids.  Other  categories  over-
represented among the genes differentially expressed were such as Oxidoreductase
activity, Iron Ion Homeostasis, and Extracellular. The lower expression of
extracellular matrix proteins was also reflected in the fibroid histology as FH-mutants
tended to have a higher level of cellularity than FH wildtypes. In addition to these GO
categories,  genes  known  to  be  activated  by  HIF  (Semenza  2003)  were  over-
represented within the genes differentially expressed, most showing higher expression
in FH-mutants.  The HIF-signature was well  concordant with findings by others who
have shown increased microvessel density in fibroids from HLRCC patients (Pollard
et al. 2005). Also, recent findings have clearly linked TCA cycle defects with HIF1
stabilisation  (Isaacs  et  al.  2005,  Selak  et  al.  2005),  and  a  gene  expression  study  on
phaeochromocytomas of various genetic backgrounds found induction HIF target
genes in VHL- and SDH-defective tumours when compared to MEN2- and NF1-
related tumours (Dahia et al. 2005).
It is of interest that glycolytic genes were so strikingly up-regulated in FH-
mutant fibroids. The glycolytic phenotype is a well known feature of cancers
(Gatenby and Gillies 2004), and increased flux of glucose in cancer cells was already
observed by Warburg (1956). Also, glycolytic enzymes such as phosphoglycerate
mutase (PGM) and glucosephosphate isomerase (GPI) that were found to be up-
regulated in FH-mutant fibroids (III) can also modulate cellular life span (Kondoh et
al. 2005). As HLRCC patients seem to have an increased risk of leiomyosarcoma
(Lehtonen et al. 2005), it might suggest that the increased expression of glycolytic
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genes in FH-mutant fibroid could lead to increased malignant potential. If this were
the case, FH mutations should also be detected in sporadic leiomyosarcomas, which
seems to be rare (Ylisaukko-Oja et al. 2006), however.
7.2.3 Reading fibroid gene expression profiles
Often the approach to tumour gene expression profiles focuses on the differences
between the lesions, aiming at defining all molecular subtypes of a particular tumour
type  (for  example  Perou  et  al.  2000).  This  would  then  lead  to  the  identification  of
specific pathways that drive each subclass, and therefore the subclass information
would have clinical implications (Sorlie et al. 2001). There are examples where
genetic dissection of a particular tumour type has lead to significant results, such as
the identification of epidermal growth factor receptor (EGFR)  mutations  in  lung
cancer as a factor determining response to a specific protein kinase inhibitor called
gefitinib (Stratton and Futreal 2004).
An alternative approach to genome-wide gene expression data could be the
identification of the common pathways deregulated in several tumour types (Rhodes
et al. 2004). If the focus is only on the differences, the things that are common,
potentially the key pathways that actually drive the tumorigenesis of the particular
tumour type, may be ignored. Recent evidence suggests that the unifying theme in
familial phaeochromocytoma development is resistance to a particular apoptotic
signal during development (Lee et al. 2005). In particular, Lee et al. have shown that
mutations in VHL, SDH, and RET interfere with the c-Jun dependent apoptotic
pathway so that it is not appropriately activated when nerve growth factor (NGF) is
withdrawn; increased survival of NF1-mutant neuronal cells in the absence of NGF
had been shown previously (Vogel et al. 1995). Lee et al. therefore proposed that the
development of phaeochromocytoma in these familial syndromes was due to
inappropriate developmental culling in some specific time-window during the
development. Still, by gene expression profiling, these tumours could be divided into
two different groups, possibly with a significant contribution from HIF-signalling
(Dahia et al. 2005). Even if the fundamental mechanism of tumorigenesis in different
classes of pheaochromocytoma is the same, the possibility remains that the activation
of pseudo-hypoxic signalling due to VHL- and SDH-mutations in some of these
tumours would promote the growth of these tumours significantly.
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These two alternative approaches on genome-wide expression data also lead to
at  least  two  different  models  for  fibroid  development  that  take  into  account  the
existing molecular data (Figure 7). According to this distinction, the genes
differentially expressed can be divided into two classes of interest, namely those
equally differentially expressed in both FH wild-type and mutant fibroids, and those
the expression of which is specifically altered in FH-mutants. Although in this study a
tendency for higher cellularity in FH-mutants was observed, and others have
identified distinct histological features in these tumours (Pollard et al. 2005), the FH-
mutant fibroid histology is very similar to that of FH wildtypes. This suggests that the
molecular pathobiology behind these lesions is also similar. Therefore, the genes that
are commonly deregulated in both classes of tumours could tell us something about
the essential  gene expression changes leading to leiomyoma formation. On the other
hand, since FH-mutants seem to have a clearly distinct expression profile, gene
expression changes specific to these lesions could tell us something about the
pathobiology specifically related to FH mutations. As discussed above, a clear HIF-
signature was observed in FH-mutant tumours (III), a difference that is very similar to
the differences observed between different types of phaeochromocytomas (Dahia et
al. 2005). Therefore, the gene expression data obtained in our study is consistent with
Model A in Figure 7, according to which all fibroids follow the same fundamental
leiomyomagenesis pathway (the yet unidentified ‘common fibroid pathway’) with an
additional HIF-signature that could lead to increased cellularity (III), activation of the
glycolytic genes (III), and higher microvessel density (Pollard et al. 2005) in these
tumours. Also, that no significantly differentially expressed genes could be identified
between 7QD and N7Q fibroids supports this model (II). Alternatively, the fact that
FH-mutant fibroids had a significantly different gene expression profile from FH
wild-type fibroids could be interpreted as to support Model B in Figure 7. In this case,
the focus should be put on the genes differentially expressed between these two
classes of fibroids. In either case, when designing further studies, the problem of
making testable hypotheses based on the identification of the lists of differentially



















Additional pathways (e.g. HIF), probably
also promoting tumour growth
Figure 7. Two models for leiomyomagenesis. In A, each genetic defect leads to the activation of the
common fibroid pathway which drives the tumorigenesis. Additional pathways may also contribute to
leiomyomagenesis,  but  they  are  not  the  key  pathways  driving  the  pathogenesis.  In  B,  each  genetic
lesion activates a pathway that is unique to that particular lesion resulting in biologically distinct
subgroups of fibroids. A combination of these 2 models is also possible.
The derivation of meaningful predictions from the lists of differentially
expressed genes has proven difficult. Several approaches have been developed,
mostly relying on Gene Ontology annotations (Khatri and Draghici 2005), to analyse
lists of genes in groups instead of only looking at individual genes. In some cases, the
identification of a previously identified coregulated group of genes within the list of
differentially expressed genes can be relatively easily interpreted. An example of this
is the up-regulation of glycolysis related genes in FH-mutant fibroids (III). Previous
experiments had already shown that HIF1 regulates the expression of these genes
(Semenza et al. 1994), leading to a relatively easily experimentally testable hypothesis
regarding FH-mutant fibroid biology. In this case, others have published experimental
evidence  that  the  down-regulation  of  either  FH or  SDH leads  to  the  stabilisation  of
HIF1  and subsequent up-regulation of HIF1 target genes (Isaacs et al. 2005, Selak et
al. 2005). Therefore the observation that glycolysis genes were up-regulated in FH-
mutant fibroids could be interpreted as a signature of the HIF1 signalling, and in fact,
the group comprising known HIF target genes was also significantly enriched within
the differentially expressed genes (III). Often, however, it is hard to interpret a
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relative over-representation of a particular gene ontology category within a list. For
example, it is hard to formulate reasonably testable hypotheses from an observation
that 9 out of 51 muscle contraction-related genes are enriched within the list of
differentially expressed genes with a p-value of 0.0002 (III). Four of them were
down-regulated and 5 up-regulated in FH-mutant fibroids when compared to FH
wildtypes. Firstly, one could argue, that even if 9 of the genes are deregulated, there
are still 42 genes the expression of which are not significantly altered. Can one,
therefore, argue that the muscle contraction machinery is differentially expressed?
Also, it might be that several of the genes involved in muscle contraction are
expressed more than required for actual muscle contraction, and that only some of
these genes have a function that regulate the amount of contraction. The question
would then be, are some of these deregulated genes regulatory genes?
Even if the conclusion would be that the pathway is truly differentially
expressed, it would still be hard to derive testable hypothesis from the observation.
The deregulation of these kinds of gene sets that seem to have a common function is a
vague observation and the causes leading to this apparently coordinated change in
gene expression are hard to predict. Therefore, designing an experimental setting
where one or more follow-up hypotheses could be tested may be extremely difficult.
Especially, when the follow-up studies are typically very labour intensive, the
evidence backing the predictions up should be as robust as possible.
If  the  use  of  gene  groups  based  on  similar  function  cannot  be  used  in  the
further analysis of gene expression data, what would be the proper way forward?
There are examples of studies where previous knowledge of functionally coregulated
genes have been utilised in identifying some regulatory programmes in the existing
data from gene expression profiling (Mootha et al. 2003a, and 2003b). For example,
gene set enrichment analysis (GSEA) has identified coordinated changes of PGC-1
responsive genes in diabetic muscle (Mootha et al. 2003b). In addition, from
previously published data, the same method was able to detect coordinated changes of
genes from chromosomal regions commonly harbouring gross genetic alterations
(Subramanian et al. 2005). Both of these observations, the activation of a transcription
factor and a gross chromosomal deletion or amplification, can easily be put forward
into hypotheses that can be experimentally tested. Therefore, it seems that a more
direct link than merely a similar function or cellular location should be available
between the different genes within a group before reasonable conclusions can be
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drawn. To this end, several recent studies have brought new hope by trying to identify
the regulatory regions of the human genome (Hallikas et al. 2006, Lim et al. 2005,
Xie et al. 2005) and the combination of these kind of results with methods such as
GSEA are likely to make the interpretation of microarray data significantly easier in
the near future. Alternatively, a thorough understanding of the functional modules and
regulatory circuits governing cellular processes, such as muscle contraction, might
facilitate the prediction of the consequences of differential expression of individual
genes. Such methods are being developed under the umbrella term ‘systems biology’
(Nurse 2003).
8  CONCLUSIONS
H1)  A subset of early-onset renal cell carcinomas (RCC) is caused by HLRCC
With regard to H1, no definitive conclusions can be made. The fact that 19 out of 84
index cases had a family history indicating a possible hereditary syndrome, suggests
that in early-onset RCC, familial predisposition could play a significant role.
However, there is no evidence that any of these 19 cases would be caused by HLRCC.
One out of these 19 families was studied further, as the phenotype lead to an
alternative hypothesis related to SDH. Subsequent experiments detected a truncating
SHDB mutation in a cardiac paraganglioma and a clear-cell RCC, with some areas of
eosinophilic staining. An additional family with paraganglioma and RCC segregating
a germline SDHB mutation was also found in a Polish-German registry of
phaeochromocytomas and paragangliomas. This was the first time extra-paraganglial
tumours were detected in the SDHB-neoplasia syndrome, suggesting a novel form of
hereditary RCC, and having immediate clinical implications for the follow-up of both
patients with early-onset RCC and paraganglioma or phaeochromocytoma.
H2)  Chromosome 7q21-31 harbours a leiomyoma suppressor gene
Several previous studies have indicated that 7q-deletions could play a role in
leiomyomagenesis. We detected AI in 11 out of 166 fibroids from 51 patients, and
further studies confirmed that AI was caused by chromosomal deletions. In addition,
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in  a  separate  set  of  UK  samples,  8  fibroids  with  7q  AI  were  detected,  all  of  which
showed  a  deletion.  With  the  high-resolution  aCGH,  the  smallest  commonly  deleted
region was 2.79 Mb, no homozygous deletions were observed. When new and
previously published data were combined, the smallest common region of AI was
delimited by the clone AC005070 and marker D7S496, covering only 2.3 Mb. The
gene expression studies showed a subtle overall reduction in the expression of the
genes within the common region of AI, but none of the genes stood out as a striking
candidate suppressor. The 10 known genes within this region were sequenced for
coding region and splice-site junction mutations in order to find a second hit. No
mutations were detected.
The deletion mapping data is consistent with H2, as frequently deleted regions
have been shown to harbour tumour suppressor genes. However, as no mutations in
the known protein-coding genes were detected,  it  is  not possible to implicate any of
the genes within the common region of AI in leiomyomagenesis. Also, the data is not
sufficient to exclude any of these genes from the list of putative suppressor
candidates. Thus, the data does not strongly corroborate nor reject H2.
H3)  Uterine leiomyomas carrying a 7q-deletion form a biologically distinct
subgroup of leiomyomas
The global gene expression profiles of fibroids with and without 7q AI were studied
by oligonucleotide microarray chips. These two groups did not separate from each
other with unsupervised methods, indicating that the global expression pattern does
not differ significantly. Similarly, no statistically significantly differentially expressed
genes could be identified between these two groups. Thus, the microarray data
indicates that 7q-deletions do not have a major impact on the fibroid gene expression
profile, and therefore it may be postulated that these two groups of fibroids are
biologically relatively similar. The data does not support H3.
H4)  Fumarate hydratase-deficient uterine leiomyomas form a biologically distinct
subgroup of leiomyomas
A global gene expression analysis of FH-mutant and wild-type fibroid was performed.
A clear separation of these groups could be observed with unsupervised methods,
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indicating that FH-mutant fibroids, both sporadic and HRLCC, have a distinct gene
expression profile. In addition, the data suggests that two hits in FH are required for
this distinctive expression profile to develop. Several significantly differentially
expressed genes could be identified between these two groups, and they tended to be
involved in carbohydrate metabolism. Also, a significant induction of hypoxia-
inducible factor target genes was detected in FH-mutant  fibroids.  Based  on  gene
expression data, FH-mutant fibroids have distinct biological properties that separate
them from fibroids with wild-type FH, thus supporting H4. However, as the
mechanisms driving fibroid initiation and progression are not known, based on this




The  research  described  herein  has  attempted  to  answer  some  of  the  questions  that
arose after the clinical identification of the syndrome HLRCC and its molecular
background. As is the case with most scientific discoveries, the detection of FH
mutations  in  HLRCC  families  lead  to  a  large  number  of  new  problems,  new
questions. Again, by trying to answer them, new questions arise. The results from this
project have provided answers to a minority of the questions, but still, a large number
of new questions have arisen. Is there a unifying mechanism behind the FH- and
SDH-related  neoplasia?  Why  are  the  tumour  spectra  different  between  these  two
tumour predisposition syndromes? Is the driving mechanism similar behind all uterine
leiomyomas?  Does  the  difference  in  fibroid  expression  profiles  mean  that  the
biological mechanisms behind different fibroids are truly different? If not, what role
does the HIF-signature play in HLRCC fibroids? Which of the differentially
expressed genes drive the leiomyomagenesis? Can the different expression profiles be
explained by activation or inactivation of specific transcription factors? Thus, the
initial clinical observation has lead to an exponentially expanding sequence of new
scientific problems. By solving these problems we will hopefully be able to provide
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